

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
18 August 2005 (18.08.2005)

PCT

(10) International Publication Number  
WO 2005/075504 A1

(51) International Patent Classification<sup>7</sup>: C07K 7/00,  
16/18, A61K 39/00

(21) International Application Number:  
PCT/US2004/024360

(22) International Filing Date: 29 July 2004 (29.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
PCT/US04/02892 2 February 2004 (02.02.2004) US  
PCT/US04/02894 2 February 2004 (02.02.2004) US

(71) Applicant (for all designated States except US): TANOX,  
INC. [—/US]; 10301 Stella Link Road, Houston, TX  
77025 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SINGH, Sanjaya  
[IN/US]; 5506 Kuldell Drive, Houston, TX 77096 (US).  
HUANG, Danyang [US/US]; 8181 Fannin St., Apt.  
131, Houston, TX (US). FUNG, Sek, Chung, Michael  
[US/US]; 3511 Deal, Houston, TX 77025 (US).

(74) Agent: LILJESTRAND, Cheryl, A.; Tanox, Inc., 10301  
Stella Link Road, Houston, TX 77025 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,

ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

— as to applicant's entitlement to apply for and be granted  
a patent (Rule 4.17(ii)) for the following designations AE,  
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,  
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,  
EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,  
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,  
MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,  
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,  
TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM,  
ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA,  
SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ,  
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,  
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
SN, TD, TG)

— as to the applicant's entitlement to claim the priority of the  
earlier application (Rule 4.17(iii)) for the following desig-  
nations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW,  
BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ,  
EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID,  
IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,  
LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ,  
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM,  
ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA,  
SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ,  
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,  
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
SN, TD, TG)

**Published:**

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: IDENTIFICATION OF NOVEL IgE EPITOPES

(57) Abstract: The present invention relates to novel peptide epitopes derived from the CH3 domain of IgE which are recognized by high affinity antibodies that specifically bind IgE. These novel peptides may be used for both active immunization of a subject by administering these peptides to generate high affinity antibodies in a subject, as well as for generating high affinity anti-IgE antibodies in non-human hosts that specifically bind to these regions of IgE for passive immunization of a subject.

WO 2005/075504 A1

## Identification of Novel IgE Epitopes

### CROSS RELATED APPLICATIONS

[0001] The present application claims priority to PCT Application No. PCT/US04/02892 and PCT/US04/02894 filed Feb. 2, 2004, all of which are incorporated by reference herein.

### BACKGROUND OF THE INVENTION

[0002] Allergy is a hypersensitive state induced by an exaggerated immune response to a foreign agent, such as an allergen. Immediate (type I) hypersensitivity, characterized by allergic reactions immediately following contact with the allergen, is mediated via B cells and is based on antigen-antibody reactions. Delayed hypersensitivity is mediated via T cells and based on mechanisms of cellular immunity. In recent years, the term "allergy" has become more and more synonymous with type I hypersensitivity.

[0003] Immediate hypersensitivity is a response based on the production of antibodies of the immunoglobulin class E (IgE antibodies) by B cells which upon exposure to an allergen differentiate into antibody secreting plasma cells. The IgE induced reaction is a local event occurring at the site of the allergen's entry into the body, i.e. at mucosal surfaces and/or at local lymph nodes. Locally produced IgE will first sensitize local mast cells, i.e. IgE antibodies bind with their constant regions to Fc $\epsilon$  receptors on the surface of the mast cells, and then "spill-over" IgE enters the circulation and binds to receptors on both circulating basophils and tissue-fixed mast cells throughout the body. When the bound IgE is subsequently contacted with the allergen, the Fc $\epsilon$  receptors are crosslinked by binding of the allergen causing the cells to degranulate and release a number of anaphylactic mediators such as histamine, prostaglandins, leukotrienes, etc. It is the release of these substances which is responsible for the clinical symptoms typical of immediate hypersensitivity, namely contraction of smooth muscle in the respiratory tract or the intestine, the dilation of small blood vessels and the increase in their permeability to water and plasma proteins, the secretion of mucus resulting, e.g in allergic rhinitis, atopic excema and asthma, and the stimulation of nerve endings in the skin resulting in itching and pain. In addition, the reaction upon second contact with the allergen is intensified because some B

cells form a "memory pool" of surface IgE positive B cells (sIgE<sup>+</sup> B cells) after the first contact with the allergen by expressing IgE on the cell surface.

[0004]

There are two major receptors for IgE, the high affinity receptor FcεRI and the low-affinity receptor FcεRII. FcεRI is predominantly expressed on the surface of mast cells and basophils, but low levels of FcεRI can also be found on human Langerhan's cells, dendritic cells, and monocytes, where it functions in IgE-mediated allergen presentation. In addition, FcεRI has been reported on human eosinophils and platelets (Hasegawa, S. et al., *Hematopoiesis*, 1999, 93:2543-2551). FcεRI is not found on the surface of B cells, T cells, or neutrophils. The expression of FcεRI on Langerhan's cells and dermal dendritic cells is functionally and biologically important for IgE-bound antigen presentation in allergic individuals (Klupal R. et al., *J. Invest. Dermatol.* 1997, 108 (3):336-42).

[0005]

The low-affinity receptor, FcεRII (CD23) is a lectin-like molecule comprising three identical subunits with head structures extending from a long α-helical coiled stalk from the cellular plasma membrane (Dierks, A.E. et al., *J. Immunol.* 1993, 150:2372-2382). Upon binding to IgE, FcεRII associates with CD21 on B cells involved in the regulation of synthesis of IgE (Sanon, A. et al., *J. Allergy Clin. Immunol.* 1990, 86:333-344, Bonnefoy, J. et al., *Eur. Resp. J.* 1996, 9:63s-66s). FcεRII has long been recognized for allergen presentation (Sutton and Gould, 1993, *Nature*, 366:421-428). IgE bound to FcεRII on epithelial cells is responsible for specific and rapid allergen presentation (Yang, P.P., *J. Clin. Invest.*, 2000, 106:879-886). FcεRII is present on several cell types, including B-cells, eosinophils, platelets, natural killer cells, T-cells, follicular dendritic cells, and Langerhan's cells.

[0006]

The structural entities on the IgE molecule that interact with FcεRI and FcεRII have also been identified. Mutagenesis studies have indicated that the CH3 domain mediates IgE interaction with both FcεRI (Presta et al., *J. Biol. Chem.* 1994, 269:26368-26373; Henry A.J. et al., *Biochemistry*, 1997, 36:15568-15578) and FcεRII (Sutton and Gould, *Nature*, 1993, 366: 421-428; Shi, J. et al., *Biochemistry*, 1997, 36:2112-2122). The binding sites for both high- and low-affinity receptors are located symmetrically along a central rotational axis through the two CH3 domains. The FcεRI-binding site is located in a CH3 domain on the

outward side near the junction of the CH2 domain, whereas the FcεRII-binding site is on the carboxyl-terminus of CH3.

[0007] A promising concept for the treatment of allergy involves the application of monoclonal antibodies, which are IgE isotype-specific and are thus capable of binding IgE. This approach is based on the inhibition of allergic reactions by downregulating the IgE immune response, which is the earliest event in the induction of allergy and provides for the maintenance of the allergic state. As the response of other antibody classes is not affected, both an immediate and a long lasting effect on allergic symptoms is achieved. Early studies of human basophil density showed a correlation between the level of IgE in the plasma of a patient and the number of FcεRI receptors per basophil (Malveaux *et al.*, *J. Clin. Invest.*, 1978, 62:176). They noted that the FcεRI densities in allergic and non-allergic persons range from  $10^4$  to  $10^6$  receptors per basophil. Later it was shown that treatment of allergic diseases with anti-IgE decreased the amount of circulating IgE to 1% of pretreatment levels (MacGlashan *et al.*, *J. Immunol.*, 1997, 158:1438-1445). MacGlashan analyzed serum obtained from patients treated with whole anti-IgE antibody, which binds free IgE circulating in the serum of the patient. They reported that lowering the level of circulating IgE in a patient resulted in a lower number of receptors present on the surface of basophils. Thus, they hypothesized that FcεRI density on the surface of basophils and mast cells is directly or indirectly regulated by the level of circulating IgE antibody.

[0008] More recently, WO 99/62550 disclosed the use of IgE molecules and fragments, which bind to FcεRI and FcεRII IgE binding sites to block IgE binding to receptors. However, effective therapies that lack deleterious side effects for the management of these allergic diseases are limited. One therapeutic approach to treating allergic diseases involved using humanized anti-IgE antibody to treat allergic rhinitis and asthma (Corne, J. *et al.*, *J. Clin. Invest.* 1997, 99:879-887; Racine-Poon, A. *et al.*, *Clin. Pharmacol. Ther.* 1997, 62:675-690; Fahy, J.V. *et al.*, *Am. J. Resp. Crit. Care Med.* 1997, 155:1824-1834; Boulet, L. P. *et al.*, *Am. J. Resp. Crit. Care Med.*, 1997, 155:1835-1840; Milgrom, E. *et al.*, *N. Engl. J. Med.*, 1999, 341:1966-1973). These clinical data demonstrate that inhibition of IgE binding to its receptors is an effective approach to treating allergic diseases.

- [0009] Antibodies suitable as anti-allergic agents should react with surface IgE positive B cells which differentiate into IgE producing plasma cells, so that they can be used to functionally eliminate those B cells. However, antibodies to IgE in principle may also induce mediator release from IgE sensitized mast cells by crosslinking the Fc $\epsilon$  receptors, thus antagonizing the beneficial effect exerted on the serum IgE and sIgE<sup>+</sup> B cell level. One of the potentially dangerous problems with developing anti-IgE therapies is the possibility of IgE-crosslinking caused by the therapeutic antibody binding to IgE already bound to the high affinity receptor and triggering histamine release resulting in a potentially anaphylactic reaction.
- [0010] Therefore, antibodies applicable for therapy of allergy must not be capable of reacting with IgE bound on sensitized mast cells and basophils, but should retain the capability to recognize sIgE<sup>+</sup> B cells. Such IgE isotype-specific antibodies have been described e.g. by Chang et al. (Biotechnology 8, 122-126 (1990)), in European Patent No. EP0407392, and several U.S. Patents, e.g., U.S. Patent No. 5,449,760.
- [0011] Peptides used to generate anti-IgE antibodies also suffer from the dangerous potential to induce anaphylactic antibodies. Generation of anti-IgE antibodies during active vaccination may be capable of triggering histamine release in the same way passively administered anti-IgE antibodies, if the antibodies generated during immunization bind to IgE bound to the high affinity IgE receptor or by other mechanisms.
- [0012] Thus, there is a need for higher affinity non-anaphylactic antibodies that bind specifically to IgE but do not bind IgE already bound to its high affinity receptor, as well as peptides for active immunization that do not induce anaphylactic antibodies. The inventors have identified the specific epitope of IgE that provides high affinity binding of antibodies without binding to IgE on mast cells or basophils. These specific epitopes can in turn be used to generate specific peptides for active immunization to generate antibodies to IgE that only bind to the region of IgE that binds to the receptor, ensuring that the antibodies do not crosslink IgE already bound to the receptor and thus are non-anaphylactic.

**SUMMARY OF THE INVENTION**

- [0013] The present invention relates to novel peptide epitopes derived from the CH3 domain of IgE. These peptide epitopes are recognized by high affinity antibodies that specifically bind IgE. These novel peptides may be used for both the active immunization of a mammal by administering these peptides to generate high affinity antibodies in the mammal. The peptide epitopes may also be used in generating high affinity anti-IgE antibodies in a non-human host that specifically bind to these regions of IgE and use the resulting antibodies for the passive immunization of a of a mammal.
- [0014] One immunogen (epitope A, Fig. 11) of the present invention comprises the amino acid sequence:  
Asn Pro Arg Gly Val Ser Xaa Tyr Xaa Xaa Arg Xaa (SEQ ID NO. 72).  
One example of epitope A is:  
Asn Pro Arg Gly Val Ser Ala Tyr Leu Ser Arg Pro (SEQ ID NO. 73)  
Another immunogen (epitope B, Fig. 11) comprises the amino acid sequence:  
Leu Pro Arg Ala Leu Xaa Arg Ser Xaa (SEQ ID NO. 74).  
Examples of Epitope B include:  
Leu Pro Arg Ala Leu Met Arg Ser Thr (SEQ ID NO. 75)  
His Pro His Leu Pro Arg Ala Leu Met Arg Ser Thr (SEQ ID NO 76)  
Leu Pro Arg Ala Leu Met Arg Ser Thr Thr Lys Thr (SEQ ID NO 77).  
In either SEQ ID NO: 72 or SEQ ID NO: 74, Xaa may be any amino acid.
- [0015] These peptides may be included in a composition comprising at least one of the peptides and a physiologically acceptable carrier, diluent, stabilizer or excipient, as well as an immunogenic carrier. The immunogenic carrier may be, e.g., BSA, KLH, tetanus toxoid, and diphtheria toxoid. The present invention also relates to polynucleotides encoding SEQ ID NOS. 72-77, vectors comprising said polynucleotides, and cells harboring said vectors.
- [0016] The present invention also relates to antibodies that specifically bind to epitope A and/or epitope B. The present invention is also directed to a method of making antibodies that specifically bind to epitope A and/or epitope B.
- [0017] The present invention relates to the administration of peptides comprising SEQ ID NO: 72 and/or SEQ ID NO 74 to a subject suffering from an IgE-mediated disease or condition.

[0018] The present invention relates to the administration of high affinity antibodies generated using peptides comprising SEQ ID NO: 72 and/or SEQ ID NO 74 to a mammal suffering from an IgE-mediated disease or condition. The high affinity antibody may be human, humanized, or chimeric. The antibody may be polyclonal or monoclonal. Such IgE mediated diseases or conditions include, e.g., asthma, atopic dermatitis, urticaria, allergic rhinitis and eczema.

#### **BRIEF DESCRIPTION OF THE FIGURES**

- [0019] Figure 1 is a schematic representation of the phage vector used in antibody cloning and screening.
- [0020] Figure 2 is a schematic representation of oligonucleotides useful in generating antibody variants.
- [0021] Figure 3A depicts the comparison of the light chains of the murine anti-IgE antibody TES-C21 and the combined human template of L16 and JK4.
- [0022] Figure 3B depicts the comparison of the heavy chains of TES-C21 and the combined human template DP88 and JH4b.
- [0023] Figure 4 presents a table of the framework residue variants having high affinity as compared to the parent TES-C21.
- [0024] Figure 5A and B depict the ELISA titration curves for clones 4, 49, 72, 78, and 136, as compared to the parent Fab of TES-C21 and negative control (5D12).
- [0025] Figure 6 depicts an inhibition assay of clones 2C, 5A, and 5I, as compared to the parent TES-C21 and a negative control antibody.
- [0026] Figure 7A depicts the sequences of clones having a combination of beneficial mutations which resulted in even greater affinity for IgE.
- [0027] Figure 8A & 8B depict the framework sequences of the entire light chain variable region for clones 136, 1, 2, 4, 8, 13, 15, 21, 30, 31, 35, 43, 44, 53, 81, 90, and 113.
- [0028] Figure 9A & 9B depict the framework sequences of the entire heavy chain variable region for 35 clones.
- [0029] Figures 10 A-F depict the complete heavy and light chain sequences for clones 136, 2C, 5I, 5A, 2B, and 1136-2C.
- [0030] Figure 11 depicts the CH3 region amino acid sequence of human IgE and highlights Epitope "A" and Epitope "B".
- [0031] Figure 12 depicts the overlapping peptides used to identify Epitope B.

[0032] Figure 13 depicts the identification of important residues in the binding region of Epitope A.

[0033] Figure 14 depicts the identification of important residues in the binding region of Epitope B.

[0034] Figure 15 depicts a western blot analysis of MAb binding to mutant peptides.

[0035] Figure 16 depicts the generation of anti-IgE antibodies in a transgenic animal expressing human IgE.

## **DETAILED DESCRIPTION OF THE INVENTION**

### Definitions

[0036] Terms used throughout this application are to be construed with ordinary and typical meaning to those of ordinary skill in the art. However, Applicants desire that the following terms be given the particular definition as defined below.

[0037] The phrase "substantially identical" with respect to an antibody chain polypeptide sequence may be construed as an antibody chain exhibiting at least 70%, or 80%, or 90% or 95% sequence identity to the reference polypeptide sequence. The term with respect to a nucleic acid sequence may be construed as a sequence of nucleotides exhibiting at least about 85%, or 90%, or 95% or 97% sequence identity to the reference nucleic acid sequence.

[0038] The term "identity" or "homology" shall be construed to mean the percentage of amino acid residues in the candidate sequence that are identical with the residue of a corresponding sequence to which it is compared, after aligning the sequences and introducing gaps, if necessary to achieve the maximum percent identity for the entire sequence, and not considering any conservative substitutions as part of the sequence identity. Neither N- or C-terminal extensions nor insertions shall be construed as reducing identity or homology. Methods and computer programs for the alignment are well known in the art. Sequence identity may be measured using sequence analysis software.

[0039] The term "antibody" is used in the broadest sense, and specifically covers monoclonal antibodies (including full length monoclonal antibodies), polyclonal antibodies, and multispecific antibodies (e.g., bispecific antibodies). Antibodies (Abs) and immunoglobulins (Igs) are glycoproteins having the same structural characteristics. While antibodies exhibit binding specificity to a specific target, immunoglobulins include both antibodies and other antibody-like molecules which



lack target specificity. Native antibodies and immunoglobulins are usually heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light (L) chains and two identical heavy (H) chains. Each heavy chain has at one end a variable domain ( $V_H$ ) followed by a number of constant domains. Each light chain has a variable domain at one end ( $V_L$ ) and a constant domain at its other end. "High affinity" antibodies refers to those antibodies having a binding affinity of at least  $10^{-10}$ , preferably  $10^{-12}$ .

[0040] As used herein, "anti-human IgE antibody" means an antibody which binds to human IgE in such a manner so as to inhibit or substantially reduce the binding of such IgE to the high affinity receptor, Fc $\epsilon$ RI.

[0041] The term "variable" in the context of variable domain of antibodies, refers to the fact that certain portions of the variable domains differ extensively in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular target. However, the variability is not evenly distributed through the variable domains of antibodies. It is concentrated in three segments called complementarity determining regions (CDRs) also known as hypervariable regions both in the light chain and the heavy chain variable domains. The more highly conserved portions of variable domains are called the framework (FR). The variable domains of native heavy and light chains each comprise four FR regions, largely adopting a  $\beta$ -sheet configuration, connected by three CDRs, which form loops connecting, and in some cases forming part of, the  $\beta$ -sheet structure. The CDRs in each chain are held together in close proximity by the FR regions and, with the CDRs from the other chain, contribute to the formation of the target binding site of antibodies (see Kabat et al.) As used herein, numbering of immunoglobulin amino acid residues is done according to the immunoglobulin amino acid residue numbering system of Kabat et al., (Sequences of Proteins of Immunological Interest, National Institute of Health, Bethesda, Md. 1987), unless otherwise indicated.

[0042] The term "antibody fragment" refers to a portion of a full-length antibody, generally the target binding or variable region. Examples of antibody fragments include Fab, Fab', F(ab')<sub>2</sub> and Fv fragments. The phrase "functional fragment or analog" of an antibody is a compound having qualitative biological activity in common with a full-length antibody. For example, a functional fragment or analog of an anti-IgE

antibody is one which can bind to an IgE immunoglobulin in such a manner so as to prevent or substantially reduce the ability of such molecule from having the ability to bind to the high affinity receptor, FcεRI. As used herein, "functional fragment" with respect to antibodies, refers to Fv, F(ab) and F(ab')<sub>2</sub> fragments. An "Fv" fragment is the minimum antibody fragment which contains a complete target recognition and binding site. This region consists of a dimer of one heavy and one light chain variable domain in a tight, non-covalent association (V<sub>H</sub>-V<sub>L</sub> dimer). It is in this configuration that the three CDRs of each variable domain interact to define an target binding site on the surface of the V<sub>H</sub>-V<sub>L</sub> dimer. Collectively, the six CDRs confer target binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an target) has the ability to recognize and bind target, although at a lower affinity than the entire binding site. "Single-chain Fv" or "sFv" antibody fragments comprise the V<sub>H</sub> and V<sub>L</sub> domains of an antibody, wherein these domains are present in a single polypeptide chain. Generally, the Fv polypeptide further comprises a polypeptide linker between the V<sub>H</sub> and V<sub>L</sub> domains which enables the sFv to form the desired structure for target binding.

[0043] The Fab fragment contains the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxyl terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region. F(ab') fragments are produced by cleavage of the disulfide bond at the hinge cysteines of the F(ab')<sub>2</sub> pepsin digestion product. Additional chemical couplings of antibody fragments are known to those of ordinary skill in the art.

[0044] The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single targetic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the target. In addition to their specificity, monoclonal antibodies are advantageous in that they

may be synthesized by the hybridoma culture, uncontaminated by other immunoglobulins. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies for use with the present invention may be isolated from phage antibody libraries using the well known techniques. The parent monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler and Milstein, Nature 256, 495 (1975), or may be made by recombinant methods.

- [0045] "Humanized" forms of non-human (e.g. murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')<sub>2</sub> or other target-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody may also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin template chosen.
- [0046] The terms "cell", "cell line" and "cell culture" include progeny. It is also understood that all progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. Variant progeny that have the same function or biological property, as screened for in the originally transformed cell, are included. The "host cells" used in the present invention generally are prokaryotic or eukaryotic hosts.
- [0047] "Transformation" of a cellular organism with DNA means introducing DNA into an organism so that the DNA is replicable, either as an extrachromosomal element or by chromosomal integration. "Transfection" of a cellular organism with DNA refers to the taking up of DNA, e.g., an expression vector, by the cell or organism whether or not any coding sequences are in fact expressed. The terms "transfected host cell" and "transformed" refer to a cell in which DNA was introduced. The cell is termed "host cell" and it may be either prokaryotic or eukaryotic. Typical prokaryotic host cells include various strains of E. coli. Typical

eukaryotic host cells are mammalian, such as Chinese hamster ovary or cells of human origin. The introduced DNA sequence may be from the same species as the host cell of a different species from the host cell, or it may be a hybrid DNA sequence, containing some foreign and some homologous DNA.

[0048] The term "vector" means a DNA construct containing a DNA sequence which is operably linked to a suitable control sequence capable of effecting the expression of the DNA in a suitable host. Such control sequences include a promoter to effect transcription, an optional operator sequence to control such transcription, a sequence encoding suitable mRNA ribosome binding sites, and sequences which control the termination of transcription and translation. The vector may be a plasmid, a phage particle, or simply a potential genomic insert. Once transformed into a suitable host, the vector may replicate and function independently of the host genome, or may in some instances, integrate into the genome itself. In the present specification, "plasmid" and "vector" are sometimes used interchangeably, as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of vectors which serve equivalent function as and which are, or become, known in the art.

[0049] The expression "control sequences" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers. DNA for a presequence or secretory leader may be operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous.

- [0050] "Mammal" for purposes of treatment refers to any animal classified as a mammal, including human, domestic and farm animals, nonhuman primates, and zoo, sports, or pet animals, such as dogs, horses, cats, cows, etc.
- [0051] The term "epitope tagged" when used herein in the context of a polypeptide refers to a polypeptide fused to an "epitope tag". The epitope tag polypeptide has enough residues to provide an epitope against which an antibody can be made, yet is short enough such that it does not interfere with activity of the polypeptide. The epitope tag preferably also is fairly unique so that the antibody does not substantially cross-react with other epitopes. Suitable tag polypeptides generally have at least 6 amino acid residues and usually between about 8-50 amino acid residues (preferably between about 9-30 residues). Examples include the flu HA tag polypeptide and its antibody 12CA5 (Field et al, Mol Cell. Biol. 8: 2159-2165 (1988)); the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereagainst (Evan et al., Mol Cell. Biol. 5(12): 3610-3616 (1985)); and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody (Paborsky et al., Protein Engineering 3(6): 547-553 (1990)). In certain embodiments, the epitope tag may be an epitope of the Fc region of an IgG molecule (e.g., IgG1, IgG2, IgG3 or IgG4) that is responsible for increasing the in vivo serum half-life of the IgG molecule.
- [0052] The word "label" when used herein refers to a detectable compound or composition which can be conjugated directly or indirectly to a molecule or protein, e.g., an antibody. The label may itself be detectable (e.g., radioisotope labels or fluorescent labels) or, in the case of an enzymatic label, may catalyze chemical alteration of a substrate compound or composition which is detectable.
- [0053] As used herein, "solid phase" means a non-aqueous matrix to which the antibody of the present invention can adhere. Example of solid phases encompassed herein include those formed partially or entirely of glass (e.g. controlled pore glass), polysaccharides (e.g., agarose), polyacrylamides, polystyrene, polyvinyl alcohol and silicones. In certain embodiments, depending on the context, the solid phase can comprise the well of an assay plate; in others it is a purification column (e.g. an affinity chromatography column).
- [0054] As used herein, the term "IgE-mediated disorder" means a condition or disease which is characterized by the overproduction and/or hypersensitivity to the immunoglobulin IgE. Specifically it would be construed to include conditions

associated with anaphylactic hypersensitivity and atopic allergies, including for example: asthma, allergic rhinitis & conjunctivitis (hay fever), eczema, urticaria, atopic dermatitis, and food allergies. The serious physiological condition of anaphylactic shock caused by, e.g., bee stings, snake bites, food or medication, is also encompassed under the scope of this term.

### **Generation of Antibodies**

- [0055] The starting or "parent" antibody may be prepared using techniques available in the art for generating such antibodies. These techniques are well known. Exemplary methods for generating the starting antibody are described in more detail in the following sections. These descriptions are possible alternatives for making or selecting a parent antibody and in no way limit the methods by which such a molecule may be generated.
- [0056] The antibody's binding affinity is determined prior to generating a high affinity antibody of the present invention. Also, the antibody may be subjected to other biological activity assays, e.g., in order to evaluate effectiveness as a therapeutic. Such assays are known in the art and depend on the target and intended use for the antibody.
- [0057] To screen for antibodies which bind to a particular epitope (e.g., those which block binding of IgE to its high affinity receptor), a routine cross-blocking assay such as that described in "Antibodies: A Laboratory Manual" (Cold Spring Harbor Laboratory, Ed Harlow and David Lane (1988)) can be performed. Alternatively, epitope mapping can be performed to determine where the antibody binds an epitope of interest. Optionally, the binding affinity of the antibody for a homolog of the target used to generate the antibody (where the homolog is from a different species) may be assessed using techniques known in the art. In one embodiment, the other species is a nonhuman mammal to which the antibody will be administered in preclinical studies. Accordingly, the species may be a nonhuman primate, such as rhesus, cynomolgus, baboon, chimpanzee and macaque. In other embodiments, the species may be a rodent, cat or dog, for example.
- [0058] The parent antibody is altered according to the present invention so as to generate an antibody which has a higher or stronger binding affinity for the target than the parent antibody. Antibody specificity results from the unique interface that is formed between the antibody and its target; the surfaces complement each

other to produce a unique fit (Jones, S. & Thornton, J. M. (1996) *Proc. Natl. Acad. Sci. USA* 93: 13-20). By further improving the contacts along this interface, the overall affinity can increase as a result of the lower energy cost needed to favor the association of the binding partners.

[0059] The binding surface of the antibody is generally composed of six complementarity determining regions (CDRs) which are loops that extend out from the core. The CDRs are composed of amino acids having a sequence that is unique for binding to the specific target. To increase the affinity of an antibody for its antigen, the environment around these amino acids must become more favorable by introducing or improving various noncovalent forces, which ultimately lowers the energetics of the interaction, resulting in higher affinity.

[0060] Van der Waals forces are noncovalent interactions which occur between two electrically neutral molecules (Voet, D. & Voet, J. G. (1990) *Biochemistry* John Wiley and Sons, NY, NY). Associations can occur between two surfaces from electrostatic interactions that arise from permanent or induced dipoles. These dipoles can exist along the ends of  $\alpha$ -helices or near polar amino acids. By increasing the number of van der Waals forces along a binding interface, a more favorable association will result.

[0061] Introducing hydrogen bonds will also increase the specificity of an interaction between an antibody and its antigen. Common donors and acceptors involved in hydrogen bonding are nitrogen, oxygen and sulfur atoms, of which amino acids are predominantly composed (See Voet, et al., *supra*). Hydrogen bonds tend to cross only short distances (usually 2.7 to 3.1 Å), hence the binding partners must come within close proximity for these interactions to occur. Thus, one manner by which affinity can be improved is to bring potential donor and acceptor molecules into close contact to establish hydrogen bonds.

[0062] Finally, improving the hydrophobic interactions will also increase the favorable energetics between two binding partners. The nonpolar residues that lie close to the binding surface should be surrounded by other nonpolar residues, and thus will exist in a favorable environment. By satisfying the burial of nonpolar side chains, the energetics of the interaction are favorable for a strong binding interface.

- [0063] Interactions that stabilize the protein-protein interface lower the energetic cost of maintaining these contacts and thus will increase the overall affinity. By improving the environment around individual amino acids that are near the binding interface, a more favorable environment is produced resulting in higher binding affinity. Therefore, by introducing favorable contacts and improving the interface through further complementation, the overall binding interaction between antibody and antigen will be greatly improved.
- [0064] The resulting high affinity antibody preferably has a binding affinity for the target which is at least about 10 fold higher, or at least about 20 fold higher, or at least about 500 fold higher or may be 1000 to 5000 fold higher, than the binding affinity of the parent antibody for the target. The degree of enhancement in binding affinity necessary or desired will depend on the initial binding affinity of the parent antibody.
- [0065] In general, the method for making high affinity antibodies from a parent antibody involves the following steps:
- [0066] 1. Obtaining or selecting a parent antibody which binds the target of interest, which comprises heavy and light chain variable domains. This may be done by traditional hybridoma techniques, phage-display techniques, or any other method of generating a target specific antibody.
- [0067] 2. Selecting a framework sequence which is close in sequence to the parent framework, preferably a human template sequence. This template may be chosen based on, e.g., its comparative overall length, the size of the CDRs, the amino acid residues located at the junction between the framework and the CDRs, overall homology, etc. The template chosen can be a mixture of more than one sequence or may be a consensus template.
- [0068] 3. Generating a library of clones by making random amino acid substitutions at each and every possible CDR position. One may also randomly substitute the amino acids in the human framework template that are, e.g., adjacent to the CDRs or that may affect binding or folding, with all possible amino acids, generating a library of framework substitutions. These framework substitutions can be assessed for their potential effect on target binding and antibody folding. The substitution of amino acids in the framework may be done either simultaneously or



sequentially with the substitution of the amino acids in the CDRs. One method for generating the library of variants by oligonucleotide synthesis.

[0069] 4. Constructing an expression vector comprising the heavy and/or light chain variants generated in step (3) which may comprise the formulas: FRH1-CDRH1-FRH2-CDRH2-FRH3-CDRH3-FRH4(I) and FRL1-CDRL1-FRL2-CDRL2-FRL3-CDRL3-FRL4 (II), wherein FRL1, FRL2, FRL3, FRL4, FRH1, FRH2, FRH3 and FRH4 represent the variants of the framework template light chain and heavy chain sequences chosen in step 3 and the CDRs represent the variant CDRs of the parent antibody CDRs. An example of a vector containing such light and heavy chain sequences is depicted in Figure 1.

[0070] 5. Screening the library of clones against the specific target and those clones that bind the target are screened for improved binding affinity. Those clones that bind with greater affinity than the parent molecule may be selected. The optimal high affinity candidate will have the greatest binding affinity possible compared to the parent antibody, preferably greater than 20 fold, 100 fold, 1000 fold or 5000 fold. If the chosen variant contains certain amino acids that are undesirable, such as a glycosylation site that has been introduced or a potentially immunogenic site, those amino acids may be replaced with more beneficial amino acid residues and the binding affinity reassessed.

[0071] One may also use this method to generate high affinity antibodies from a fully human parent antibody by randomly substituting only the CDR regions, leaving the human framework intact.

[0072] Due to improved high throughput screening techniques and vectors such as the one depicted in Figure 1, an artisan can rapidly and efficiently screen a comprehensive library of substitutions at all sites in a given CDR and/or framework region. By randomly substituting all amino acids at all positions simultaneously, one is able to screen possible combinations that significantly increase affinity that would not have been anticipated or identified by individual substitution due to, e.g., synergy.

## **PARENT ANTIBODY PREPARATION**

### **Target Preparation**

[0073] Soluble targets or fragments thereof can be used as immunogens for generating antibodies. The antibody is directed against the target of interest. Preferably, the

target is a biologically important polypeptide and administration of the antibody to a mammal suffering from a disease or disorder can result in a therapeutic benefit in that mammal. However, antibodies may be directed against non polypeptide targets. Where the target is a polypeptide, it may be a transmembrane molecule (e.g. receptor) or ligand such as a growth factor. One target of the present invention is IgE. Whole cells may be used as the immunogen for making antibodies. The target may be produced recombinantly or made using synthetic methods. The target may also be isolated from a natural source.

[0074] Antigens used in producing antibodies of the invention may include polypeptides and polypeptide fragments of the invention, including epitope A and/or B. A polypeptide used to immunize an animal can be obtained by standard recombinant, chemical synthetic, or purification methods. As is well known in the art, in order to increase immunogenicity, an antigen can be conjugated to a carrier protein. Commonly used carriers include, but are not limited to, keyhole limpet hemocyanin (KLH), thyroglobulin, bovine serum albumin (BSA), and tetanus toxoid. The coupled peptide is then used to immunize an animal (e.g., a mouse, a rat, or a rabbit). In addition to such carriers, well known adjuvants can be administered with the antigen to facilitate induction of a strong immune response.

#### **Polyclonal Antibodies**

[0075] Polyclonal antibodies are usually generated in non-human mammals by multiple subcutaneous (sc) or intraperitoneal (ip) injections of the relevant target in combination with an adjuvant. Numerous agents capable of eliciting an immunological response are well known in the art.

[0076] Animals are immunized against the target, immunogenic conjugates, or derivatives by combining the protein or conjugate (for rabbits or mice, respectively) with Freund's complete adjuvant and injecting the solution intradermally. One month later the animals are boosted with 1/5 to 1/10 the original amount of peptide or conjugate in Freund's incomplete adjuvant by subcutaneous injection at multiple sites. Seven to 14 days later the animals are bled and the serum is assayed for antibody titer. Animals are boosted until the titer plateaus.

[0077] The mammalian antibody selected will normally have a sufficiently strong binding affinity for the target. For example, the antibody may bind the human anti-IgE

target with a binding affinity (Kd) value of about  $1 \times 10^{-8}$  M. Antibody affinities may be determined by saturation binding; enzyme-linked immunoabsorbant assay (ELISA); and competition assays (e.g., radioimmunoassays).

- [0078] To screen for antibodies that bind the target of interest, a routine cross-linking assay such as that described in *Antibodies, A Laboratory Manual*, Cold Spring Harbor Laboratory, Ed Harlow and David Lane (1988) can be performed. Alternatively, epitope mapping, e.g., as described in Champe, et al. *J. Biol. Chem.* 270: 1388-1394 (1995), can be performed to determine binding.

#### **Monoclonal Antibodies**

- [0079] Monoclonal antibodies are antibodies which recognize a single antigenic site. Their uniform specificity makes monoclonal antibodies much more useful than polyclonal antibodies, which usually contain antibodies that recognize a variety of different antigenic sites. Monoclonal antibodies may be made using the hybridoma method first described by Kohler et al., *Nature*, 256: 495 (1975), or may be made by recombinant DNA methods.
- [0080] In the hybridoma method, a mouse or other appropriate host animal, such as a rodent, is immunized as hereinabove described to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization. Alternatively, lymphocytes may be immunized in vitro. Lymphocytes then are fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, *Monoclonal Antibodies: Principals and Practice*, pp. 590-103 (Academic Press, 1986)).
- [0081] The hybridoma cells thus prepared are seeded and grown in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells. For example, if the parental myeloma cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT medium), substances which prevent the growth of HGPRT-deficient cells. Preferred myeloma cells are those that fuse efficiently, support stable high-level production of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. Human myeloma and mouse-human heteromyeloma cell lines have been described for the production of human monoclonal antibodies (Kozbar, J.

Immunol. 133: 3001 (1984); Brodeur et al., *Monoclonal Antibody Production Techniques and Applications*, pp. 51-63 (Marcel Dekker, Inc., New York, 1987)).

[0082] After hybridoma cells are identified that produce antibodies of the desired specificity, affinity, and/or activity, the clones may be subcloned by limiting dilution procedures and grown by standard methods (Goding, *Monoclonal Antibodies: Principles and Practice*, pp. 59-103, Academic Press, 1986)). Suitable culture media for this purpose include. The monoclonal antibodies secreted by the subclones are suitably separated from the culture medium by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

[0083] DNA encoding the monoclonal antibodies is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the monoclonal antibodies). The hybridoma cells serve as a source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transferred into host cells such as *E. coli* cells, NS0 cells, Chinese hamster ovary (CHO) cells, or myeloma cells to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also may be modified, for example, by substituting the coding sequence for human heavy- and light-chain constant domains in place of the homologous murine sequences (U.S. Pat. No. 4,816,567; Morrison et al., *Proc. Natl Acad. Sci. USA* 81: 6851 (1984)), or by covalently joining to the immunoglobulin polypeptide.

#### **Humanized Antibodies**

[0084] Humanization is a technique for making a chimeric antibody wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. A humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be essentially performed following the method of Winter and co-workers (Jones et al, *Nature* 321: 522-525 (1986); Riechman et al., *Nature* 332: 323-327 (1988); Verhoeyens et al., *Science* 239: 1534-1536 (1988)), by

substituting non-human CDR's or CDR sequences for the corresponding sequences in a human antibody (See, e.g., U.S. Pat. No. 4,816,567). As practiced in the present invention, the humanized antibody may have some CDR residues and some FR residues substituted by residues from analogous sites in murine antibodies.

[0085] The choice of human variable domains, both light and heavy, to be used in making the humanized antibodies is very important to reduce antigenicity. According to the so-called "best fit" method, the sequence of the variable domain of a non-human antibody is compared with the library of known human variable-domain sequences. The human sequence which is closest to that of the non-human parent antibody is then accepted as the human framework for the humanized antibody (Sims et al., J. Immunol. 151: 2296 (1993); Chothia et al., J. Mol. Biol. 196: 901 (1987)). Another method uses a particular framework derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework may be used for several different humanized antibodies (Carter et al., Proc. Natl. Acad. Sci. USA, 89: 4285 (1992); Presta et al., J. Immunol. 151: 2623 (1993)).

#### **Antibody Fragments**

[0086] Various techniques have been developed for the production of antibody fragments. Traditionally, these fragments were derived via proteolytic digestion of intact antibodies (see, e.g., Morimoto et al., Journal of Biochemical and Biophysical Methods 24: 107-117 (1992) and Brennan et al., Science 229: 81 (1985)). However, these fragments can now be produced directly by recombinant host cells. For example, the antibody fragments can be isolated from an antibody phage library. Alternatively, F(ab')<sub>2</sub>-SH fragments can be directly recovered from *E. coli* and chemically coupled to form F(ab')<sub>2</sub> fragments (Carter et al., Bio/Technology 10: 163-167 (1992)). According to another approach, F(ab')<sub>2</sub> fragments can be isolated directly from recombinant host cell culture. Other techniques for the production of antibody fragments will be apparent to the skilled practitioner. In other embodiments, the antibody of choice is a single chain Fv fragment (scFv). (PCT patent application WO 93/16185).

## PREPARATION OF HIGH AFFINITY ANTIBODIES

- [0087] Once the parent antibody has been identified and isolated, one or more amino acid residues may be altered in one or more of the variable regions of the parent antibody. Alternatively, or in addition, one or more substitutions of framework residues may be introduced in the parent antibody where these result in an improvement in the binding affinity of the antibody, for example, for human IgE. Examples of framework region residues to modify include those which non-covalently bind target directly (Amit et al. *Science* 233: 747-753 (1986)); interact with/affect the conformation of CDR (Chothia et al. *J. Mol. Biol.* 196: 901-917 (1987)); and/or participate in the VL-VH interface (EP 239 400 B1). In certain embodiments, modification of one or more of such framework region residues results in an enhancement of the binding affinity of the antibody for the target of interest.
- [0088] Modifications in the antibodies' biological properties may be accomplished by selecting substitutions that differ significantly in their effect on maintaining, e.g., (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation; (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Non-conservative substitutions will entail exchanging a member of one of these classes for another class.
- [0089] Nucleic acid molecules encoding amino acid sequence variants are prepared by a variety of methods known in the art. These methods include, but are not limited to, oligonucleotide-mediated (or site-directed) mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlier prepared variant or a non-variant version of the species-dependent antibody. The preferred method for generating variants is an oligonucleotide-mediated synthesis. In certain embodiments, the antibody variant will only have a single hypervariable region residue substituted, e.g. from about two to about fifteen hypervariable region substitutions.
- [0090] One method for generating the library of variants is by oligonucleotide mediated synthesis according to the scheme depicted in Figure 2. Three oligonucleotides of approximately 100 nucleotides each may be synthesized spanning the entire light chain or heavy chain variable region. Each oligonucleotide may comprise: (1) a 60 amino acid stretch generated by the triplet (NNK)<sub>20</sub> where N is any nucleotide

and K is G or T, and (2) an approximately 15-30 nucleotide overlap with either the next oligo or with the vector sequence at each end. Upon annealing of these three oligonucleotides in a PCR reaction, the polymerase will fill in the opposite strand generating a complete double stranded heavy chain or light chain variable region sequence. The number of triplets may be adjusted to any length of repeats and their position within the oligonucleotide may be chosen so as to only substitute amino acids in a given CDR or framework region. By using (NNK), all twenty amino acids are possible at each position in the encoded variants. The overlapping sequence of 5-10 amino acids (15-30 nucleotides) will not be substituted, but this may be chosen to fall within the stacking regions of the framework, or may be substituted by a separate or subsequent round of synthesis. Methods for synthesizing oligonucleotides are well known in the art and are also commercially available. Methods for generating the antibody variants from these oligonucleotides are also well known in the art, e.g., PCR.

[0091] The library of heavy and light chain variants, differing at random positions in their sequence, can be constructed in any expression vector, such as a bacteriophage, specifically the vector of Fig.1, each of which contains DNA encoding a particular heavy and light chain variant.

[0092] Following production of the antibody variants, the biological activity of variant relative to the parent antibody is determined. As noted above, this involves determining the binding affinity of the variant for the target. Numerous high-throughput methods exist for rapidly screen antibody variants for their ability to bind the target of interest.

[0093] One or more of the antibody variants selected from this initial screen may then be screened for enhanced binding affinity relative to the parent antibody. One common method for determining binding affinity is by assessing the association and dissociation rate constants using a BIAcore™ surface plasmon resonance system (BIAcore, Inc.). A biosensor chip is activated for covalent coupling of the target according to the manufacturer's (BIAcore) instructions. The target is then diluted and injected over the chip to obtain a signal in response units (RU) of immobilized material. Since the signal in RU is proportional to the mass of immobilized material, this represents a range of immobilized target densities on the matrix. Dissociation data are fit to a one-site model to obtain  $k_{off}$  +/- s.d.

(standard deviation of measurements). Pseudo-first order rate constant ( $k_s$ ) are calculated for each association curve, and plotted as a function of protein concentration to obtain  $k_{on}$  +/- s.e. (standard error of fit). Equilibrium dissociation constants for binding,  $K_D$ 's, are calculated from SPR measurements as  $k_{off}/k_{on}$ . Since the equilibrium dissociation constant,  $K_D$ , is inversely proportional to  $k_{off}$ , an estimate of affinity improvement can be made assuming the association rate ( $k_{on}$ ) is a constant for all variants.

[0094] The resulting candidate(s) with high affinity may optionally be subjected to one or more further biological activity assays to confirm that the antibody variant(s) with enhanced binding affinity still retain the desired therapeutic attributes. For example, in the case of an anti-IgE antibody, one may screen for those that block binding of IgE to its receptor and inhibit the release of histamine. The optimal antibody variant retains the ability to bind the target with a binding affinity significantly higher than the parent antibody.

[0095] The antibody variant(s) so selected may be subjected to further modifications oftentimes depending upon the intended use of the antibody. Such modifications may involve further alteration of the amino acid sequence, fusion to heterologous polypeptide(s) and/or covalent modifications such as those elaborated below. For example, any cysteine residues not involved in maintaining the proper conformation of the antibody variant may be substituted, generally with serine, to improve the oxidative stability of the molecule and prevent aberrant cross linking. Conversely, (a) cysteine bond(s) may be added to the antibody to improve its stability (particularly where the antibody is an antibody fragment such as an Fv fragment).

### **VECTORS**

[0096] The invention also provides isolated nucleic acid encoding an antibody variant as disclosed herein, vectors and host cells comprising the nucleic acid, and recombinant techniques for the production of the antibody variant. For recombinant production of the antibody variant, the nucleic acid encoding it is isolated and inserted into a replicable vector for further cloning (amplification of the DNA) or for expression. DNA encoding the antibody variant is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide



probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibody variant).

[0097] Many vectors are available. The vector components generally include, but are not limited to, one or more of the following: a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence.

[0098] The phage expression vector depicted in Figure 1 is comprised of a commonly used M13 vector and M13's own gene III viral secretion signal for rapid secretion and screening variant Fabs for proper binding specificity and minimal affinity criteria. This vector does not use the entire gene III sequence, so there is no display on the surface of the bacterial cell, but rather the Fabs are secreted into the periplasmic space. Alternatively, the Fabs could be expressed in the cytoplasm and isolated. The heavy and light chains each have their own viral secretion signal, but are dependently expressed from a single strong inducible promoter.

[0099] The vector in Figure 1 also provides a His tag and a myc tag for easy purification, as well as detection. A skilled artisan would recognize that the Fabs could be independently expressed from separate promoters or that the secretion signal need not be the viral sequence chosen, but could be a prokaryotic or eukaryotic signal sequence suitable for the secretion of the antibody fragments from the chosen host cell. It should also be recognized that the heavy and light chains may reside on different vectors.

#### **A. Signal Sequence Component**

[0100] The antibody variant of this invention may be produced recombinantly. The variant may also be expressed as a fusion polypeptide fused with a heterologous polypeptide, which is preferably a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide. The heterologous signal sequence selected preferably is one that is recognized and processed (i.e., cleaved by signal peptidase) by the host cell. For prokaryotic host cells that do not recognize and process the native antibody signal sequence, the signal sequence may be substituted by a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, lpp, or heat-stable enterotoxin II leaders. Or in the case of the vector of Figure 1, the

signal sequence chosen was a viral signal sequence from gene III. For yeast secretion the native signal sequence may be substituted by, e.g., the yeast invertase leader,  $\alpha$ -factor leader (including *Saccharomyces* and *Kluyveromyces*  $\alpha$ -factor leaders), or acid phosphatase leader, the *C. albicans* glucoamylase leader, or a signal described in e.g., WO 90/13646. In mammalian cell expression, mammalian signal sequences as well as viral secretory leaders, for example, the herpes simplex gD signal, are available. The DNA for such precursor region is ligated in reading frame to DNA encoding the antibody variant.

### **B. Origin of Replication Component**

[0101] Vectors usually contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Generally, this sequence is one that enables the vector to replicate independently of the host chromosomal DNA, and includes origins of replication or autonomously replicating sequences. Such sequences are well known for a variety of bacteria, yeast, and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the  $2\mu$  plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for vectors in mammalian cells. Generally, the origin of replication component is not needed for mammalian expression vectors (the SV40 origin may typically be used only because it contains the early promoter).

### **C. Selection Gene Component**

[0102] Vectors may contain a selection gene, also termed a selectable marker. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for Bacilli.

[0103] One example of a selection scheme utilizes a drug to arrest growth of a host cell. Those cells that are successfully transformed with a heterologous gene produce a protein conferring drug resistance and thus survive the selection regimen. Examples of such dominant selection use the drugs neomycin, mycophenolic acid and hygromycin.

- [0104] Another example of suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the antibody nucleic acid, such as DHFR, thymidine kinase, metallothionein-I and -II, preferably primate metallothionein genes, adenosine deaminase, ornithine decarboxylase, etc.
- [0105] For example, cells transformed with the DHFR selection gene are first identified by culturing all of the transformants in a culture medium that contain methotrexate (Mtx), a competitive antagonist of DHFR. An appropriate host cell when wild-type DHFR is employed is the Chinese hamster ovary (CHO) cell line deficient in DHFR activity.
- [0106] Alternatively, host cells (particularly wild-type hosts that contain endogenous DHFR) transformed or co-transformed with DNA sequences encoding antibody, wild-type DHFR protein, and another selectable marker such as aminoglycoside 3'-phosphotransferase (APH) can be selected by cell growth in medium containing a selection agent for the selectable marker such as an aminoglycosidic antibiotic, e.g., kanamycin, neomycin, or G418. (U.S. Pat. No. 4,965,199).
- [0107] A suitable selection gene for use in yeast is the *trp1* gene present in the yeast plasmid Yrp7 (Stinchcomb et al., Nature 282: 39 (1979)). The *trp1* gene provides a selection marker for a variant strain of yeast lacking the ability to grow in typtophan, for example, ATCC No. 44076 or PEP4-1. Jones, Genetics 85: 12 (1977). The presence of the *trp1* lesion in the yeast host cell genome then provides an effective environment for detecting transformation by growth in the absence of tryptophan. Similarly, Leu2-deficient yeast strains (ATCC 20,622 or 38,626) are complemented by known plasmids bearing the Leu2 gene.

#### **D. Promoter Component**

- [0108] Expression and cloning vectors usually contain a promoter that is recognized by the host organism and is operably linked to the antibody nucleic acid. Promoters suitable for use with prokaryotic hosts include the *phoA* promoter,  $\beta$ -lactamase and lactose promoter systems, alkaline phosphatase, a tryptophan (*trp*) promoter system, and hybrid promoters such as the *tac* promoter. However, other known bacterial promoters are suitable. Promoters for use in bacterial systems may also contain a Shine-Dalgarno (S.D.) sequence operably linked to the DNA encoding the antibody.

- [0109] Promoter sequences are known for eukaryotes. Virtually all eukaryotic genes have an AT-rich region located approximately 25 to 30 bases upstream from the site where transcription is initiated. Another sequence found 70 to 80 bases upstream from the start of transcription of many genes is a CNCAAT region where N may be any nucleotide. At the 3' end of most eukaryotic genes is an AATAAA sequence that may be the signal for addition of the poly A tail to the 3' end of the coding sequence. All of these sequences are suitably inserted into eukaryotic expression vectors.
- [0110] Examples of suitable promoter sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase or other glycolytic enzymes, such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.
- [0111] Other yeast promoters, which are inducible promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in EP 73,657. Yeast enhancers also are advantageously used with yeast promoters.
- [0112] Antibody transcription from vectors in mammalian host cells is controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus, adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and most preferably Simian virus 40 (SV40), from heterologous mammalian promoters, e.g., the actin promoter or an immunoglobulin promoter, from heat-shock promoters-- provided such promoters are compatible with the host cell systems.
- [0113] The early and late promoters of the SV40 virus are conveniently obtained as an SV40 restriction fragment that also contains the SV40 viral origin of replication. The immediate early promoter of the human cytomegalovirus is conveniently obtained as a HindIII E restriction fragment. A system for expressing DNA in

mammalian hosts using the bovine papilloma virus as a vector is disclosed in U.S. Pat. No. 4,419,446. A modification of this system is described in U.S. Pat. No. 4,601,978. Alternatively, human  $\beta$ -interferon cDNA has been expressed in mouse cells under the control of a thymidine kinase promoter from herpes simplex virus. Alternatively, the rous sarcoma virus long terminal repeat can be used as the promoter.

#### **E. Enhancer Element Component**

[0114] Transcription of a DNA encoding the antibody of this invention by higher eukaryotes is often increased by inserting an enhancer sequence into the vector. Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin,  $\alpha$ -fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. See also Yaniv, Nature 297: 17-18 (1982) on enhancing elements for activation of eukaryotic promoters. The enhancer may be spliced into the vector at a position 5' or 3' to the antibody-encoding sequence, but is preferably located at a site 5' from the promoter.

#### **F. Transcription Termination Component**

[0115] Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human, or nucleated cells from other multicellular organisms) may also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and, occasionally 3', untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding the antibody. One useful transcription termination component is the bovine growth hormone polyadenylation region. See e.g., WO94/11026.

#### **SELECTION AND TRANSFORMATION OF HOST CELLS**

[0116] Suitable host cells for cloning or expressing the DNA in the vectors herein are prokaryotic, yeast, or higher eukaryotic cells. Suitable prokaryotes for this purpose include both Gram-negative and Gram-positive organisms, for example, Enterobacteria such as *E. coli*, *Enterobacter*, *Erwinia*, *Klebsiella*, *Proteus*,

*Salmonella*, *Serratia*, and *Shigella*, as well as Bacilli, Pseudomonas, and Streptomyces. One preferred *E. coli* cloning host is *E. coli* 294 (ATCC 31,446), although other strains such as *E. coli* B, *E. coli* X1776 (ATCC 31,537), and *E. coli* W3110 (ATCC 27,325) are suitable. These examples are illustrative rather than limiting.

- [0117] In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody-encoding vectors. *Saccharomyces cerevisiae* is the most commonly used among lower eukaryotic host microorganisms. However, a number of other genera, species, and strains are commonly available and useful herein, such as *Schizosaccharomyces pombe*; *Kluyveromyces*; *Candida*; *Trichoderma*; *Neurospora crassa*; and filamentous fungi such as e.g., *Neurospora*, *Penicillium*, *Tolyocladium*, and *Aspergillus* hosts, such as *A. nidulans* and *A. niger*.
- [0118] Suitable host cells for the expression of glycosylated antibodies are derived from multicellular organisms. In principal, any higher eukaryotic cell culture is workable, whether from vertebrate or invertebrate culture. Examples of invertebrate cells include plant and insect cells, Luckow et al., *Bio/Technology* 6, 47-55 (1988); Miller et al., *Genetic Engineering*, Setlow et al. eds. Vol. 8, pp. 277-279 (Plenum publishing 1986); Mseda et al., *Nature* 315, 592-594 (1985). Numerous baculoviral strains and variants and corresponding permissive insect host cells from hosts such as *Spodoptera frugiperda* (caterpillar), *Aedes* (mosquito), *Drosophila melanogaster* (fruitfly), and *Bombyx mori* have been identified. A variety of viral strains for transfection are publicly available, e.g., the L-1 variant of *Autographa californica* NPV and the Bm-5 strain of *Bombyx mori* NPV, and such viruses may be used as the virus herein according to the present invention, particularly for transfection of *Spodoptera frugiperda* cells. Moreover, plant cells cultures of cotton, corn, potato, soybean, petunia, tomato, and tobacco and also be utilized as hosts.
- [0119] Vertebrate cells and propagation of vertebrate cells, in culture (tissue culture) has become routine. See *Tissue Culture*, Academic Press, Kruse and Patterson, eds. (1973). Examples of useful mammalian host cell lines are monkey kidney; human embryonic kidney line; baby hamster kidney cells; Chinese hamster ovary cells/-DHFR (CHO, Urlaub et al., *Proc. Natl. Acad. Sci. USA* 77: 4216 (1980)); mouse

sertoli cells; human cervical carcinoma cells (HELA); canine kidney cells; human lung cells; human liver cells; mouse mammary tumor; and NS0 cells.

[0120] Host cells are transformed with the above-described vectors for antibody production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.

[0121] The host cells used to produce the antibody variant of this invention may be cultured in a variety of media. Commercially available media such as Ham's F10 (Sigma), Minimal Essential Medium (MEM, Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium (DMEM, Sigma) are suitable for culturing host cells. In addition, any of the media described in Ham et al., Meth. Enzymol. 58: 44 (1979), Barnes et al., Anal. Biochem. 102: 255 (1980), U.S. Pat. Nos. 4,767,704; 4,657,866; 4,560,655; 5,122,469; 5,712,163; or 6,048,728 may be used as culture media for the host cells. Any of these media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as X-chlorides, where X is sodium, calcium, magnesium; and phosphates), buffers (such as HEPES), nucleotides (such as adenosine and thymidine), antibiotics (such as GENTAMYCIN.TM. drug), trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art. The culture conditions, such as temperature, pH, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.

#### **ANTIBODY PURIFICATION**

[0122] When using recombinant techniques, the antibody variant can be produced intracellularly, in the periplasmic space, or directly secreted into the medium. If the antibody variant is produced intracellularly, as a first step, the particulate debris, either host cells or lysed fragments, may be removed, for example, by centrifugation or ultrafiltration. Carter et al., Bio/Technology 10: 163-167 (1992) describe a procedure for isolating antibodies which are secreted to the periplasmic space of E. coli. Briefly, cell paste is thawed in the presence of sodium acetate

(pH 3.5), EDTA, and phenylmethylsulfonylfluoride (PMSF) over about 30 minutes. Cell debris can be removed by centrifugation. Where the antibody variant is secreted into the medium, supernatants from such expression systems are generally first concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit. A protease inhibitor such as PMSF may be included in any of the foregoing steps to inhibit proteolysis and antibiotics may be included to prevent the growth of adventitious contaminants.

[0123] The antibody composition prepared from the cells can be purified using, for example, hydroxylapatite chromatography, gel electrophoresis, dialysis, and affinity chromatography, with affinity chromatography being the preferred purification technique. The suitability of protein A as an affinity ligand depends on the species and isotype of any immunoglobulin Fc domain that is present in the antibody variant. Protein A can be used to purify antibodies that are based on human IgG1, IgG2 or IgG4 heavy chains (Lindmark et al., J. Immunol Meth. 62: 1-13 (1983)). Protein G is recommended for all mouse isotypes and for human IgG3 (Guss et al., EMBO J. 5: 1567-1575 (1986)). The matrix to which the affinity ligand is attached is most often agarose, but other matrices are available. Mechanically stable matrices such as controlled pore glass or poly(styrenedivinyl)benzene allow for faster flow rates and shorter processing times than can be achieved with agarose. Where the antibody variant comprises a CH3 domain, the Bakerbond ABXTM resin (J. T. Baker, Phillipsburg, N.J.) is useful for purification. Other techniques for protein purification such as fractionation on an ion-exchange column, ethanol precipitation, Reverse Phase HPLC, chromatography on silica, chromatography on heparin SEPHAROSE™ chromatography on an anion or cation exchange resin (such as a polyaspartic acid column), chromatofocusing, SDS-PAGE, and ammonium sulfate precipitation are also available depending on the antibody variant to be recovered.

[0124] Following any preliminary purification step(s), the mixture comprising the antibody variant of interest and contaminants may be subjected to low pH hydrophobic interaction chromatography using an elution buffer at a pH between about 2.5-4.5, preferably performed at low salt concentrations (e.g., from about 0-0.25M salt).



**PHARMACEUTICAL FORMULATIONS**

- [0125] Therapeutic formulations of the polypeptide or antibody may be prepared for storage as lyophilized formulations or aqueous solutions by mixing the polypeptide having the desired degree of purity with optional "pharmaceutically-acceptable" carriers, excipients or stabilizers typically employed in the art (all of which are termed "excipients"). For example, buffering agents, stabilizing agents, preservatives, isotoniifiers, non-ionic detergents, antioxidants and other miscellaneous additives. (See Remington's Pharmaceutical Sciences, 16th edition, A. Osol, Ed. (1980)). Such additives must be nontoxic to the recipients at the dosages and concentrations employed.
- [0126] Buffering agents help to maintain the pH in the range which approximates physiological conditions. They are preferably present at concentration ranging from about 2 mM to about 50 mM. Suitable buffering agents for use with the present invention include both organic and inorganic acids and salts thereof such as citrate buffers (e.g., monosodium citrate-disodium citrate mixture, citric acid-trisodium citrate mixture, citric acid-monosodium citrate mixture, etc.), succinate buffers (e.g., succinic acid-monosodium succinate mixture, succinic acid-sodium hydroxide mixture, succinic acid-disodium succinate mixture, etc.), tartrate buffers (e.g., tartaric acid-sodium tartrate mixture, tartaric acid-potassium tartrate mixture, tartaric acid-sodium hydroxide mixture, etc.), fumarate buffers (e.g., fumaric acid-monosodium fumarate mixture, etc.), fumarate buffers (e.g., fumaric acid-monosodium fumarate mixture, fumaric acid-disodium fumarate mixture, monosodium fumarate-disodium fumarate mixture, etc.), gluconate buffers (e.g., gluconic acid-sodium glyconate mixture, gluconic acid-sodium hydroxide mixture, gluconic acid-potassium glyconate mixture, etc.), oxalate buffer (e.g., oxalic acid-sodium oxalate mixture, oxalic acid-sodium hydroxide mixture, oxalic acid-potassium oxalate mixture, etc.), lactate buffers (e.g., lactic acid-sodium lactate mixture, lactic acid-sodium hydroxide mixture, lactic acid-potassium lactate mixture, etc.) and acetate buffers (e.g., acetic acid-sodium acetate mixture, acetic acid-sodium hydroxide mixture, etc.). Additionally, there may be mentioned phosphate buffers, histidine buffers and trimethylamine salts such as Tris.
- [0127] Preservatives may be added to retard microbial growth, and may be added in amounts ranging from 0.2%-1% (w/v). Suitable preservatives for use with the

present invention include phenol, benzyl alcohol, meta-cresol, methyl paraben, propyl paraben, octadecyldimethylbenzyl ammonium chloride, benzalconium halides (e.g., chloride, bromide, iodide), hexamethonium chloride, alkyl parabens such as methyl or propyl paraben, catechol, resorcinol, cyclohexanol, and 3-pentanol.

[0128] Isotonicifiers sometimes known as "stabilizers" may be added to ensure isotonicity of liquid compositions of the present invention and include polyhydric sugar alcohols, preferably trihydric or higher sugar alcohols, such as glycerin, erythritol, arabitol, xylitol, sorbitol and mannitol.

[0129] Stabilizers refer to a broad category of excipients which can range in function from a bulking agent to an additive which solubilizes the therapeutic agent or helps to prevent denaturation or adherence to the container wall. Typical stabilizers can be polyhydric sugar alcohols (enumerated above); amino acids such as arginine, lysine, glycine, glutamine, asparagine, histidine, alanine, ornithine, L-leucine, 2-phenylalanine, glutamic acid, threonine, etc., organic sugars or sugar alcohols, such as lactose, trehalose, stachyose, mannitol, sorbitol, xylitol, ribitol, myoinisitol, galactitol, glycerol and the like, including cyclitols such as inositol; polyethylene glycol; amino acid polymers; sulfur containing reducing agents, such as urea, glutathione, thiocetic acid, sodium thioglycolate, thioglycerol,  $\alpha$ -monothioglycerol and sodium thio sulfate; low molecular weight polypeptides (i.e. <10 residues); proteins such as human serum albumin, bovine serum albumin, gelatin or immunoglobulins; hydrophylic polymers, such as polyvinylpyrrolidone monosaccharides, such as xylose, mannose, fructose, glucose; disaccharides such as lactose, maltose, sucrose and trisaccharides such as raffinose; polysaccharides such as dextran. Stabilizers may be present in the range from 0.1 to 10,000 weights per part of weight active protein.

[0130] Non-ionic surfactants or detergents (also known as "wetting agents") may be added to help solubilize the therapeutic agent as well as to protect the therapeutic protein against agitation-induced aggregation, which also permits the formulation to be exposed to shear surface stressed without causing denaturation of the protein. Suitable non-ionic surfactants include polysorbates (20, 80, etc.), polyoxamers (184, 188 etc.), Pluronic® polyols, polyoxyethylene sorbitan monoethers (TWEEN®-20, TWEEN®-80, etc.). Non-ionic surfactants may be

present in a range of about 0.05 mg/ml to about 1.0 mg/ml, preferably about 0.07 mg/ml to about 0.2 mg/ml.

[0131] Additional miscellaneous excipients include bulking agents, (e.g. starch), chelating agents (e.g. EDTA), antioxidants (e.g., ascorbic acid, methionine, vitamin E), and co-solvents. The formulation herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. For example, it may be desirable to further provide an immunosuppressive agent. Such molecules are suitably present in combination in amounts that are effective for the purpose intended. The active ingredients may also be entrapped in microcapsule prepared, for example, by coascervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsule and poly-(methylmethacrylate) microcapsule, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences, 16th edition, A. Osal, Ed. (1980).

[0132] The formulations to be used for in vivo administration must be sterile. This is readily accomplished, for example, by filtration through sterile filtration membranes. Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semi-permeable matrices of solid hydrophobic polymers containing the antibody variant, which matrices are in the form of shaped articles, e.g., films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. When encapsulated antibodies remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37° C resulting in a loss of biological activity and possible changes in immunogenicity.

Rational strategies can be devised for stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S--S bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.

[0133] The amount of therapeutic polypeptide, antibody or fragment thereof which will be effective in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques. Where possible, it is desirable to determine the dose-response curve and the pharmaceutical compositions of the invention first in vitro, and then in useful animal model systems prior to testing in humans.

[0134] In a preferred embodiment, an aqueous solution of therapeutic polypeptide, antibody or fragment thereof is administered by subcutaneous injection. Each dose may range from about 0.5  $\mu\text{g}$  to about 50  $\mu\text{g}$  per kilogram of body weight, or more preferably, from about 3  $\mu\text{g}$  to about 30  $\mu\text{g}$  per kilogram body weight.

[0135] The dosing schedule for subcutaneous administration may vary from once a month to daily depending on a number of clinical factors, including the type of disease, severity of disease, and the subject's sensitivity to the therapeutic agent.

#### **USES FOR THE ANTIBODY VARIANT**

[0136] The antibody variants of the invention may be used as affinity purification agents. In this process, the antibodies are immobilized on a solid phase such as SEPHADEX™ resin or filter paper, using methods well known in the art. The immobilized antibody variant is contacted with a sample containing the target to be purified, and thereafter the support is washed with a suitable solvent that will remove substantially all the material in the sample except the target to be purified, which is bound to the immobilized antibody variant. Finally, the support is washed with another suitable solvent, such as glycine buffer, that will release the target from the antibody variant.

[0137] The variant antibodies may also be useful in diagnostic assays, e.g., for detecting expression of a target of interest in specific cells, tissues, or serum. For diagnostic applications, the antibody variant typically will be labeled with a detectable moiety. Numerous labels are available Techniques for quantifying a change in

fluorescence are described above. The chemiluminescent substrate becomes electronically excited by a chemical reaction and may then emit light which can be measured (using a chemiluminometer, for example) or donates energy to a fluorescent acceptor. Examples of enzymatic labels include luciferases (e.g., firefly luciferase and bacterial luciferase; U.S. Pat. No. 4,737,456), luciferin, 2,3-dihydrophthalazinediones, malate dehydrogenase, urease, peroxidase such as horseradish peroxidase (HRPO), alkaline phosphatase, .beta.-galactosidase, glucoamylase, lysozyme, saccharide oxidases (e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase), heterocyclic oxidases (such as uricase and xanthine oxidase), lactoperoxidase, microperoxidase, and the like. Techniques for conjugating enzymes to antibodies are described in O'Sullivan et al., *Methods for the Preparation of Enzyme-Antibody Conjugates for Use in Enzyme Immunoassay*, in *Methods in Enzym.* (Ed. J. Langone & H. Van Vunakis), Academic press, New York, 73: 147-166 (1981).

[0138] Sometimes, the label is indirectly conjugated with the antibody variant. The skilled artisan The skilled artisan will be aware of various techniques for achieving this. For example, the antibody variant can be conjugated with biotin and any of the three broad categories of labels mentioned above can be conjugated with avidin, or vice versa. Biotin binds selectively to avidin and thus, the label can be conjugated with the antibody variant in this indirect manner. Alternatively, to achieve indirect conjugation of the label with the antibody variant, the antibody variant is conjugated with a small hapten (e.g. digloxin) and one of the different types of labels mentioned above is conjugated with an anti-hapten antibody variant (e.g. anti-digloxin antibody). Thus, indirect conjugation of the label with the antibody variant can be achieved.

[0139] In another embodiment of the invention, the antibody variant need not be labeled, and the presence thereof can be detected using a labeled antibody which binds to the antibody variant.

[0140] The antibodies of the present invention may be employed in any known assay method, such as competitive binding assays, direct and indirect sandwich assays, and immunoprecipitation assays. Zola, *Monoclonal Antibodies: A Manual of Techniques*, pp. 147-158 (CRC Press, Inc. 1987).

- [0141] Competitive binding assays rely on the ability of a labeled standard to compete with the test sample for binding with a limited amount of antibody variant. The amount of target in the test sample is inversely proportional to the amount of standard that becomes bound to the antibodies. To facilitate determining the amount of standard that becomes bound, the antibodies generally are insolubilized before or after the competition. As a result, the standard and test sample that are bound to the antibodies may conveniently be separated from the standard and test sample which remain unbound.
- [0142] Sandwich assays involve the use of two antibodies, each capable of binding to a different immunogenic portion, or epitope, or the protein to be detected. In a sandwich assay, the test sample to be analyzed is bound by a first antibody which is immobilized on a solid support, and thereafter a second antibody binds to the test sample, thus forming an insoluble three-part complex. See e.g., U.S. Pat. No. 4,376,110. The second antibody may itself be labeled with a detectable moiety (direct sandwich assays) or may be measured using an anti-immunoglobulin antibody that is labeled with a detectable moiety (indirect sandwich assay). For example, one type of sandwich assay is an ELISA assay, in which case the detectable moiety is an enzyme.
- [0143] For immunohistochemistry, the tumor sample may be fresh or frozen or may be embedded in paraffin and fixed with a preservative such as formalin, for example.
- [0144] The antibodies may also be used for in vivo diagnostic assays. Generally, the antibody variant is labeled with a radionuclide (such as <sup>111</sup>In, <sup>99</sup>Tc, <sup>14</sup>C, <sup>131</sup>I, <sup>3</sup>H, <sup>32</sup>P or <sup>35</sup>S) so that the tumor can be localized using immunoscintigraphy. For example, a high affinity anti-IgE antibody of the present invention may be used to detect the amount of IgE present in, e.g., the lungs of an asthmatic patient.
- [0145] The antibody of the present invention can be provided in a kit, i.e., packaged combination of reagents in predetermined amounts with instructions for performing the diagnostic assay. Where the antibody variant is labeled with an enzyme, the kit may include substrates and cofactors required by the enzyme (e.g., a substrate precursor which provides the detectable chromophore or fluorophore). In addition, other additives may be included such as stabilizers, buffers (e.g., a block buffer or lysis buffer) and the like. The relative amounts of

various reagents may be varied widely to provide for concentrations in solution the reagents which substantially optimize the sensitivity of the assay. Particularly, the reagents may be provided as dry powders, usually lyophilized, including excipients which on dissolution will provide a reagent solution having the appropriate concentration.

#### **N VIVO USES FOR THE ANTIBODY**

It is contemplated that the antibodies of the present invention may be used to treat a mammal. In one embodiment, the antibody is administered to a nonhuman mammal for the purposes of obtaining preclinical data, for example. Exemplary nonhuman mammals to be treated include nonhuman primates, dogs, cats, rodents and other mammals in which preclinical studies are performed. Such mammals may be established animal models for a disease to be treated with the antibody or may be used to study toxicity of the antibody of interest. In each of these embodiments, dose escalation studies may be performed on the mammal. The antibody or polypeptide is administered by any suitable means, including parenteral, subcutaneous, intraperitoneal, intrapulmonary, and intranasal, and, if desired for local immunosuppressive treatment, intralesional administration. Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. In addition, the antibody variant is suitably administered by pulse infusion, particularly with declining doses of the antibody variant. Preferably the dosing is given by injections, most preferably intravenous or subcutaneous injections, depending in part on whether the administration is brief or chronic.

For the prevention or treatment of disease, the appropriate dosage of the antibody or polypeptide will depend on the type of disease to be treated, the severity and course of the disease, whether the antibody variant is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the antibody variant, and the discretion of the attending physician.

The very high affinity anti-human IgE antibodies of the invention may be suitably administered to the patient at one time or over a series of treatments.

Depending on the type and severity of the disease, about 0.1 mg/kg to 150 mg/kg (e.g., 0.1-20 mg/kg) of antibody is an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by

continuous infusion. A typical daily dosage might range from about 1 mg/kg to 100 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment is sustained until a desired suppression of disease symptoms occurs. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays. An exemplary dosing regimen for an anti-LFA-1 or anti-ICAM-1 antibody is disclosed in WO 94/04188.

[0150] The antibody variant composition will be formulated, dosed and administered in a manner consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners. The "therapeutically effective amount" of the antibody variant to be administered will be governed by such considerations, and is the minimum amount necessary to prevent, ameliorate, or treat a disease or disorder. The antibody variant need not be, but is optionally formulated with one or more agents currently used to prevent or treat the disorder in question. The effective amount of such other agents depends on the amount of antibody present in the formulation, the type of disorder or treatment, and other factors discussed above. These are generally used in the same dosages and with administration routes as used hereinbefore or about from 1 to 99% of the heretofore employed dosages.

[0151] The antibodies of the present invention which recognize IgE as their target may be used to treat "IgE-mediated disorders". These include diseases such as asthma, allergic rhinitis & conjunctivitis (hay fever), eczema, urticaria, atopic dermatitis, and food allergies. The serious physiological condition of anaphylactic shock caused by, e.g., bee stings, snake bites, food or medication, is also encompassed under the scope of this invention.

#### **ANTIBODY EPITOPE MAPPING**

[0152] The term "epitope" refers to a site on an antigen to which B and/or T cells respond. B-cell epitopes can be formed both from contiguous amino acids or noncontiguous amino acids juxtaposed by tertiary folding of a protein. Epitopes formed from contiguous amino acids are typically retained on exposure to



denaturing solvents, whereas epitopes formed by tertiary folding are typically lost on treatment with denaturing solvents. An epitope typically includes at least 3, and more usually, at least 5 or 8-10 amino acids in a unique spatial conformation.

Antibodies that recognize the same epitope can be identified in a simple immunoassay showing the ability of one antibody to block the binding of another antibody to a target antigen.

[0153] Epitope mapping of the binding site for high affinity antibodies IgE of the present invention involved Western blot analysis for binding, a peptide scan of the CH3 domain of IgE, an alanine scan of the regions that showed binding, amino acid replacement from corresponding regions of IgG1 and site directed mutagenesis.

[0154] The peptide scan of the entire CH3 domain of IgE required seventy-three overlapping peptides. Each peptide was subjected to binding by labeled anti-IgE antibodies of the present invention to determine the specific epitope(s) of IgE that block binding of IgE to its high affinity receptor. The peptide scan identified two peptides as potential anti-IgE MAb contact sites on IgE, designated Epitope 'A' and Epitope 'B' (See Figure 11). Although the Epitope 'A' and Epitope 'B' sequences are about 80 amino acids apart in the linear sequence, they are positioned close to each other in the three dimensional structure of IgE. Both are surface exposed, they overlap the FcεRI binding site of IgE, and in both peptides, there are positively charged residues of Arg and hydrophobic residues of Pro. Figure 12 illustrates the binding region of Epitope B as determined by ELISA using peptide scan.

[0155] A determination of which amino acid residues are critical for binding of high affinity antibodies within these epitopes was performed by alanine scanning mutagenesis. (Cunningham et al., "High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis" Science 244:1081-1085). Alanine was substituted for each residue of Epitope A and Epitope B and binding of high affinity monoclonal antibodies was determined. (See Example 12 below and Figures 13 and 14).

#### **ACTIVE AND PASSIVE IMMUNIZATION**

[0156] The invention also relates to pharmaceutical compositions, e.g., vaccines, comprising the peptide immunogen molecules of the present invention, including SEQ ID NO 72 and/or SEQ ID NO 74, and diluents, excipients, adjuvants, or

carriers. It further concerns a process for the preparation of an immunogen of the invention, comprising covalently coupling at least one peptide of the invention with a moiety capable of eliciting an immune response against that peptide.

[0157] It also relates to immunogenic peptides as defined above, for use as a pharmaceutical, e.g. in the treatment of IgE-mediated diseases or conditions, such as allergy and atopic dermatitis.

[0158] It further relates to a method of immunizing a mammal against IgE-mediated diseases or conditions, such as allergies and atopic dermatitis, comprising the administration of a therapeutically effective amount of the immunogenic peptides as defined above to a patient in need of such treatment.

[0159] The immunogenic peptides of the present invention, while being substantially incapable of mediating non-cytolytic histamine release, are capable of eliciting antibodies with strong serological cross-reactivity with the target amino acid sequences of Epitope A and/or Epitope B.

[0160] The initial dose of peptide (e.g. from about 0.2 mg to about 5 mg) may be administered, for example, intramuscularly, followed by repeat (booster) doses of the same at 14 to 28 days later. Doses will of course depend to some extent on the age, weight and general health of the patient. Immunization may be "active" or "passive". In "active" immunization the subject receives an immunogenic peptide of the present invention and an anti-IgE response is actively induced by the subject's immune system.

[0161] "Active" immunization, this is preferred for human use, but other mammalian species may be treated similarly, as e.g. in the dog. The term "immunogenic carrier" herein includes those materials which have the property of independently eliciting an immunogenic response in a host animal and which can be covalently coupled to polypeptide either directly via formation of peptide or ester bonds between free carboxyl, amino or hydroxyl groups in the polypeptide and corresponding groups on the immunogenic carrier material, or alternatively by bonding through a conventional bifunctional linking group, or as a fusion protein.

[0162] Examples of such immunogenic carriers include: albumins, such as BSA; globulins; thyroglobulins; hemoglobins; hemocyanins (particularly Keyhole Limpet Hemocyanin [KLH]); proteins extracted from ascaris, e.g. ascaris extracts such as those described in J. Immunol. 111 [1973] 260-268, J. Immunol. 122 [1979] 302-

308, J. Immun. 98 [1967] 893-900, a Am. J. Physiol. 199 [1960] 575-578 or purified products thereof; polylysine; polyglutamic acid; lysine-glutamic acid copolymers; copolymers containing lysine or ornithine; etc. Vaccines have been produced using diphtheria toxoid or tetanus toxoid as immunogenic carrier material (Lepow M. L. et al., J. of Infectious Diseases 150 [1984] 402-406; Coen Beuvery, E. et al., Infection and Immunity 40 [1983] 39-45) and these toxoid materials can also be used in the present invention. The purified protein derivative of tuberculin (PPD) is particularly preferred for utilization in the "active" immunization scheme since (1) it does not induce a T-cell response itself (i.e. it is in effect a "T-cell hapten"), and yet behaves as a fully processed antigen and is recognized by T-cells as such; (2) it is known to be one of the most powerful hapten "carriers" in the linked recognition mode; and (3) it can be used in humans without further testing.

[0163] The present invention also relates to polynucleotides encoding the peptides of the present invention, vectors comprising said polynucleotides, and cells harboring said vectors. In addition, active immunization may be achieved by administering the polynucleotides encoding the peptides of the present invention. Vectors suitable for such therapy are known in the art and include, e.g., adenovirus vectors.

[0164] "Passive" immunization is achieved by administering anti-IgE antibodies of the present invention, to a patient suffering from IgE-mediated disease or condition.

[0165] These antibodies can be prepared by administering an immunogenic peptide of the present invention to a non-human mammal and collecting the resultant antiserum. Improved titres can be obtained by repeated injections over a period of time. There is no particular limitation to the species of mammals which may be used for eliciting antibodies; it is generally preferred to use rabbits or guinea pigs, but horses, cats, dogs, goats, pigs, rats, cows, sheep, etc., can also be used. Antibody is recovered by collecting blood from the immunized animal after the passage of 1 to 2 weeks subsequently to the last administration, centrifuging the blood and isolating serum from the blood. Monoclonal antibodies may e.g. be human or murine.

[0166] When immunizing a subject, an antibody of the present invention can be introduced into the mammal by, e.g., intramuscular injection. However, any form

of antibody administration may be used. Any conventional liquid or solid vehicle may be employed which is acceptable to the subject and does not have adverse side effects. Phosphate-buffered saline (PBS), at a physiological pH, e.g. about pH 6.8 to 7.2, preferably about pH 7.0, may be used as a vehicle, alone or with a suitable adjuvant, such as an aluminium hydroxide-based adjuvant.

[0167] The following examples are offered by way of illustration and not by way of limitation.

## EXAMPLES

### Example 1

#### Humanization of Anti-IgE Murine MAb TES-C21

[0168] The sequences of the heavy chain variable region ( $V_H$ ) and the light chain variable region ( $V_L$ ) of murine mAb TES-C21 were compared with human antibody germline sequences available in the public databases. Several criteria were used when deciding on a template as described in step 1 above, including overall length, similar CDR position within the framework, overall homology, size of the CDR, etc. All of these criteria taken together provided a result for choosing the optimal human template as shown in the sequence alignment between TES-C21 MAb heavy and light chain sequences and the respective human template sequences depicted in Figure 3A and 3B.

[0169] In this case, more than one human framework template was used to design this antibody. The human template chosen for the  $V_H$  chain was a combination of DP88 (aa residues 1-95) and JH4b (aa residues 103-113) (See Figure 3B). The human template chosen for the  $V_L$  chain was a combination of L16 (VK subgroup III, aa residues 1-87) combined with JK4 (aa residues 98-107) (See Figure 3A). The framework homology between the murine sequence and the human template was about 70% for  $V_H$  and about 74% for  $V_L$ .

[0170] Once the template was chosen, a Fab library was constructed by DNA synthesis and overlapping PCR as described above and depicted in Fig.2. The library was composed of synthesized TES-C21 CDRs synthesized with the respective chosen human templates, DP88/JH4b and L16/JK4. The complexity of the library was 4096 ( $= 2^{12}$ ). The overlapping nucleotides encoding partial  $V_H$  and  $V_L$  sequences

were synthesized in the range of about 63 to about 76 nucleotides with 18 to 21 nucleotide overlaps.

- [0171] PCR amplification of  $V_L$  and  $V_H$  gene was performed using a biotinylated forward primer containing the specific sequence to the framework region FR1 and an overhanging sequence annealed to the end of leader sequence (GenIII) and a reverse primer from the conserved constant region (C $\kappa$  or CH1) under standard PCR conditions. The PCR product was purified by agarose gel electrophoresis, or by commercial PCR purification kit to remove unincorporated biotinylated primers and non-specific PCR.
- [0172] 5'-Phosphorylation of PCR product was performed using 2 $\mu$ g PCR product, 1 $\mu$ L of T4 polynucleotide kinase (10 units/ $\mu$ L), 2 $\mu$ L of 10x PNK buffer, 1 $\mu$ L of 10mM ATP in a total volume of 20 $\mu$ L adjusted by ddH<sub>2</sub>O. After incubating at 37°C for 45 minutes, and heat denaturation at 65°C for 10 min, the reaction volume was adjusted to 200 $\mu$ L by adding ddH<sub>2</sub>O for the next step.
- [0173] The 100 $\mu$ L of streptavidin-coated magnetic beads were washed twice with 200 $\mu$ L 2x B&W buffer and resuspended in 200 $\mu$ L 2x B&W buffer. The phosphorylated PCR product was mixed with beads, and incubated at room temperature (RT) for 16 min with mild shaking.
- [0174] The beads were sedimented and washed twice with 200 $\mu$ L 2x B&W buffer. The non-biotinylated ssDNA (minus strand) was eluted with 300 $\mu$ L freshly prepared 0.15M NaOH at RT for 10 min with mild shaking. A second NaOH elution can increase the yield slightly (optional). The eluant was centrifuged to remove any trace beads.
- [0175] The ssDNA was precipitated from the supernatant by adding 1 $\mu$ L glycogen (10mg/mL), 1/10 volume of 3M NaOAc (pH 5.2), and 2.5 volumes of EtOH. The precipitated ssDNA was then washed with 70% EtOH followed by lyophilizing for 3 min and dissolving in 20 $\mu$ L ddH<sub>2</sub>O. The ssDNA was quantitated by spotting on an ethidium bromide (EtBr) agarose plate with DNA standards, or by measuring OD<sub>260</sub>.

## Example 2

### Cloning of V<sub>H</sub> and V<sub>L</sub> into Phage-Expression Vector

- [0176] V<sub>H</sub> and V<sub>L</sub> were cloned into a phage-expression vector by hybridization mutagenesis. Uridinylated templates were prepared by infecting CJ236 *E. coli* strain (dut<sup>-</sup> ung<sup>-</sup>) with M13-based phage (phage-expression vector TN003).
- [0177] The following components [200 ng of uridinylated phage vector (8.49 kb); 92 ng phosphorylated single-stranded H chain (489 bases); 100 ng phosphorylated single-stranded L chain (525 bases); 1 μL 10X annealing buffer; adjust volume with ddH<sub>2</sub>O to 10 μL] were annealed (at about 8-fold molar ratio of insert to vector) by PCR holding the temperature at 85°C for 5 min (denaturation) and then ramping to 55°C over 1 hour. The samples were chilled on ice.
- [0178] To the annealed product the following components were added: 1.4 μL 10 X synthesis buffer; 0.5 μL T4 DNA ligase (1 unit/μL); 1 μL T4 DNA polymerase (1 unit/μL) followed by incubating on ice for 5 min, and 37°C for 1.5 hours. The product was then ethanol precipitated, and dissolved in 10 μL of ddH<sub>2</sub>O or TE.
- [0179] DNA was digested with 1 μL *Xba*I (10unit/μL) for 2 h, and heat inactivated at 65°C for 20 min. Digested DNA was transfected into 50 μL of electro-competent DH10B cells by electroporation. The resulting phage were titered by growing on XL-1Blue bacterial lawn at 37°C overnight. Clones were sequenced to confirm composition.

## Example 3

### Deep Well Culture for Library Screening

#### A. Plating Phage Library

- [0180] The phage library was diluted in LB media to achieve the desired number of plaques per plate. High titer phage was mixed with 200 μL XL-1B cell culture. 3mL LB top agar was mixed, poured onto an LB plate, and allowed to sit at room temperature for 10 minutes. The plate was incubated overnight at 37°C.

#### B. Phage Elution

- [0181] 100 μL of phage elution buffer (10mM Tris-Cl, pH 7.5, 10mM EDTA, 100mM NaCl) was added to each well of a sterile U-bottom 96 well plate. A single phage plaque from the overnight library plate was transferred with a filtered pipette tip to a well. The phage elution plate was incubated at 37°C for 1 hour. The plate may be stored at 4°C following incubation.

**C. Culture for Deep Well Plates**

[0182] XL1B cells from 50mL culture were added to 2xYT media at a 1:100 dilution. The cells were grown at 37°C in a shaker until the  $A_{600}$  was between 0.9 to 1.2.

**C. Infection with Phage in Deep Well Plates**

[0183] When the cells reached the appropriate OD, 1M IPTG (1:2000) was added to the XL1B culture. The final concentration of IPTG was 0.5mM. 750 $\mu$ L of cell culture was transferred to each well of a 96 well – deep well plate (Fisher Scientific). Each well was inoculated with 25 $\mu$ L of eluted phage. The deep well plate was placed in the shaker (250rpm) and incubated overnight at 37°C.

**D. Preparing Supernatant for ELISA Screening**

[0184] Following incubation, the deep well plates were centrifuged at 3,250 rpm for 20 minutes using the Beckman JA-5.3 plate rotor. 50 $\mu$ L of supernatant was withdrawn from each well for ELISA.

**E. Inoculation of 15mL Liquid Cultures of XL- 1 cells**

[0185] XL-1s were grown at 37°C in the shaker (250rpm) in 2xYT containing 10  $\mu$ g/mL of tetracycline until  $A_{600}$  = 0.9 to 1.2. IPTG was added at a final concentration of 0.5mM and 15mL of the culture was transferred to a 50mL conical tube for each clone to be characterized. The cells were inoculated with 10  $\mu$ L of phage from the high titer stock (titer =  $\sim 10^{11}$  pfu/mL) and incubated for 1 hour at 37°C. The cells were grown overnight at room temperature with shaking.

**F. Isolation of Soluble Fab from Periplasm**

[0186] The cells were pelleted in an IEC centrifuge at 4,500 rpm for 20 minutes. Culture medium was removed the pellet was resuspend in 650 $\mu$ L of resuspension buffer (50mM Tris, pH 8.0 containing 1mM EDTA and 500mM sucrose), vortexed, and placed on ice for 1 hour with gentle shaking. Cellular debris was removed by centrifugation at 9,000 rpm for 10 minutes at 4°C. The supernatant containing the soluble Fabs was collected and stored at 4°C.

**Example 4****Framework Modification**

[0187] There were twelve murine/human wobble residues within the framework at the potential key positions described above. Position 73 in  $V_H$  was kept as the murine residue threonine in the humanization library because this position was

determined to affect binding. It was noted, however, that threonine at VH 73 is a common human residue in the human germline V<sub>H</sub> subgroup 1 and 2.

- [0188] The framework residues that differed between the TES-C21 sequence and the human template were randomly substituted as described above and then assessed for their potential affect on target binding, and antibody folding. Potential framework residues that may have affected the binding were identified. In this case, they were residues 12, 27, 43, 48, 67, 69 in V<sub>H</sub>, and 1, 3, 4, 49, 60, 85 in V<sub>L</sub> (Kabat number system). (See Figure 4) It was later demonstrated that only positions 27 and 69 significantly affected binding in the V<sub>H</sub> region (clone number 1136-2C).
- [0189] The primary screen used was a single point ELISA (SPE) using culture media (See description below). The primary screen selected clones that that bind to the antibody's target molecule. Clones that gave equal or better signal than the parent molecule were selected for the next round of screening.
- [0190] In the second round of screening, individual phage were grown in a 15 ml bacterial culture and periplasmic preparations were used for SPE and ELISA titration assays. The clones that retained higher binding in this assay were further characterized. Once all the selected primary clones were processed, the top 10-15% clones were sequenced and the clones arranged according to sequence. Representatives from each sequence group were compared against each other and the best clones selected. Sequences from these chosen clones were combined and the effects of various combinations were evaluated.
- [0191] The constructed library was subjected to an ELISA screen for improved binding to the recombinant human IgE, SE44. Clones with binding affinity greater than murine TES-C21 Fab were isolated and sequenced. Clone ID #4, 49, 72, 76, and 136 were further characterized. ELISA titration curves for clone 4, 49, 72, 78, and 136 are shown in Figure 5A and 5B indicating that their affinity is similar to the parent, TES-C21. These clones compete with murine TES-C21 for binding to human IgE indicating that the binding epitope was not changed during the humanization process. The humanized Fabs did not bind to FcεRI-bound IgE suggesting that it is less likely that the humanized antibodies will crosslink the receptor to cause histamine release when they were constructed into divalent IgG.



[0192] Humanized clone 136 retained 5 murine heavy chain framework residues (= 94.3 % human V<sub>H</sub> framework homology), with a 100% human light chain framework selected for by affinity maturation. The inhibition of IgE binding to FcεRI by the humanized Fab was demonstrated (Figure 6).

### **Example 5**

#### **Single Point ELISA Protocol for Screening anti IgE**

[0193] Plates were coated with 2ug/mL sheep anti-human Fd in carbonate coating buffer overnight at 4°C. The coating solution was removed and the plates were blocked with 200uL/well 3% BSA/PBS for 1 hour at 37°C. After washing the plates 4x with PBS/0.1% TWEEN<sup>®</sup> (PBST), 50uL/well Fab sample (i.e., supernatant containing high titer phage and secreted Fab or periplasmic prep from DMB block, or 15mL prep) was added. Plates were incubated for 1 hour at room temperature followed by washing 4x with PBST. 50uL/well of biotinylated SE44 at 0.015ug/mL diluted in 0.5% BSA/PBS and 0.05% TWEEN<sup>®</sup> was then added. Plates were then incubated for 2 hours at room temperature and washed 4X PBST. 50uL/well StreptAvidin HRP 1:2000 dilution in 0.5% BSA/PBS and 0.05% TWEEN<sup>®</sup> was added and the plates incubated 1 hour at room temperature. Plates were washed 6x with PBST. 50uL/well TMB substrate (sigma) was added to develop and then stopped by adding 50uL/well 0.2M H<sub>2</sub>SO<sub>4</sub>.

### **Example 6**

#### **ELISA Titration: anti IgE**

[0194] Plates were coated with 0.25ug/mL (for purified Fab 0.1 ug/ml) SE44 in carbonate coating buffer overnight at 4°C. Coating solution was removed and the plates were blocked with 200uL/well 3 % BSA/PBS for 1 hour at 37°C.

[0195] The plates were washed 4x with PBS/0.1% TWEEN<sup>®</sup> (PBST). 50uL/well Fab (from 15mL periplasmic prep) was added starting with a dilution of 1:2 and diluting 3 fold serially in 0.5% BSA/PBS and .05% TWEEN<sup>®</sup>20. Plates were incubated for 2 hours at room temperature.

[0196] The plates were washed 4x with PBST and 50uL/well 1:1000 (0.8ug/ml) dilution of biotin-sheep anti human Fd in 0.5% BSA/PBS and 0.05% TWEEN<sup>®</sup> 20 was added. The plates were incubated again for 2 hours at room temperature.

[0197] Following a wash 4x with PBST, 50uL/well Neutra-avidin-AP 1: 2000(0.9 ug/ml) in 0.5% BSA/PBS and 0.05% TWEEN® 20 was added and the plates were incubated 1 hour at room temperature.

[0198] The plates were washed 4x with PBST. And developed by adding 50uL/well pNPP substrate. Development was stopped by adding 50uL/well 3M NaOH. The absorbance of each well was read at 405nm or 410nm.

## Example 7

### Protocol for Affinity Purification of M13 phage Expressed Soluble Fab

#### A. DAY 1

[0199] Two 500 mL cultures (2xYT) containing 10 mg/mL tetracycline were inoculated with 5 mL overnight stock XL1B and grown at 37°C to A600 = 0.9 to 1.2. IPTG was added to a concentration of 0.5mM. The cell culture was then infected with 200 µL phage per culture and incubated for 1 hour at 37° C with shaking. Following infection, the cells were grown at 25°C overnight with shaking.

#### B. DAY 2

[0200] Cells were pelleted at 3500 x g for 30 minutes at 4 °C in 250mL centrifuge tubes. Culture medium was aspirated and the pellets were resuspended in a total of 12-15 mL lysis buffer (Buffer A + protease inhibitor cocktail).

##### Buffer A: (1 liter)

50mM NaH<sub>2</sub>PO<sub>4</sub>                      6.9 g NaH<sub>2</sub>PO<sub>4</sub>H<sub>2</sub>O (or 6 g NaH<sub>2</sub>PO<sub>4</sub>)

300mM NaCl                              17.54 g NaCl

10mM imidazole                      0.68 g imidazole (MW 68.08)

adjust pH to 8.0 using NaOH

##### Lysis buffer:

Mix 25 mL of Buffer A with one tablet of Complete Protease Inhibitor Cocktail (Roche, Basel, Switzerland).

[0201] Resuspended cells were transferred into a 50mL conical tube and lysed with 100µL 100 mg/mL lysozyme by inverting the tube several times until the mixture moves together as a blob (due to the lysis). Cells were sonicated on ice followed by the addition of 10 µL DNase I (about 1000 units) and gently rocked at 4°C for 30 minutes. Debris was pelleted by centrifugation at 12000 x g for 30 minutes at 4 °C, using 50 mL centrifuge tubes. Supernatants were transferred to a new conical tube and stored at 4 °C.

[0202] Ni-NT agarose (Qiagen, Valencis, CA) was used to purify the soluble Fabs according to the manufacturer's protocol. The lysate was mixed with Ni-NTA and loaded into a column. The flow through was collected for SDS-PAGE analysis. The column was washed with 20 mL buffer (50mM NaH<sub>2</sub>PO<sub>4</sub>, 300mM NaCl, 15mM imidazole, adjust pH to 8.0 with NaOH) followed by a 20 mL wash with 50mM NaH<sub>2</sub>PO<sub>4</sub>, 300mM NaCl, 20mM imidazole. Fabs were eluted with 6 x 500  $\mu$ L elution buffer (50mM NaH<sub>2</sub>PO<sub>4</sub>, 300mM NaCl, 450mM imidazole, adjust pH to 8.0 with NaOH) and analyzed by SDS PAGE. Column fractions were stored at 4 °C. Column fractions were analyzed by SDS-PAGE and the fraction with the greatest amount of Fab was selected and dialyzed in PBS at 4 °C.

### **Example 8**

#### **Soluble Receptor Assay**

[0203] A 96 well assay plate suitable for ELISA was coated with 0.05 mL 0.5 $\mu$ g/mL Fc $\epsilon$ RI alpha-chain receptor coating buffer (50 mM carbonate/bicarbonate, pH 9.6) for 12 hours at 4-8°C. The wells were aspirated and 250 $\mu$ L blocking buffer (PBS, 1% BSA, pH 7.2) was added and incubated for 1 hour at 37°C. In a separate assay plate the samples and reference TES-C21 MAbs were titred from 200 to 0.001 $\mu$ g/mL by 1:4 dilutions with assay buffer (0.5% BSA and 0.05% Tween 20, PBS, pH 7.2) and an equal volume of 100ng/mL biotinylated IgE was added and the plate incubated for 2-3 hours at 25°C. The Fc $\epsilon$ RI – coated wells were washed three times with PBS and 0.05% TWEEN 20 and 50 $\mu$ L from the sample wells were transferred and incubated with agitation for 30 minutes at 25°C. Fifty  $\mu$ L/well of 1 mg/mL Streptavidin-HRP, diluted 1:2000 in assay buffer, was incubated for 30 minutes with agitation and then the plate was washed as before. Fifty  $\mu$ L/well of TMB substrate was added and color was developed. The reaction was stopped by adding an equal volume of 0.2 M H<sub>2</sub>SO<sub>4</sub> and the absorbance measured at 450nm.

### **Example 9**

#### **Binding of Antibodies to IgE-loaded Fc $\epsilon$ RI**

[0204] Antibody binding to human IgE associated with the alpha-subunit of Fc $\epsilon$ RI was determined by preincubating with 10  $\mu$ g/mL human IgE for 30 min at 4°C. Plates were washed three times followed by a one hour incubation with varying concentrations of either murine anti-human IgE MAb E-10-10 or the humanized

Fab variant. Binding of Fabs was detected with a biotin labeled anti human Fd antibody followed by SA-HRP. Murine MAb E-10-10 was detected by Goat anti-murine Ig Fc HRP-conjugated Ab.

### Example 10

#### Clone Characterization

[0205] Each candidate was assayed for binding affinity and positive clones were sequenced. Antibody variants having beneficial mutations in CDR regions that increase binding affinity were further characterized. Assays included Biacore analysis; inhibition of IgE binding to its receptor; and cross linking of receptor bound IgE.

[0206] A library of variants was created. The amino acid sequences for the various CDRs which demonstrated improved affinity are depicted in Table 1. Figure 7 presents high affinity candidates having combinations of substitutions.

TABLE 1.

CDRL1:		CDRH1:	
P RASQSIGTNIH	SEQ ID NO 5	P MYWLE	SEQ ID NO 15
#1 RASRSIGTNIH	SEQ ID NO 6	#1 WYWLE	SEQ ID NO 16
#2 RASQRIGTNIH	SEQ ID NO 7	#2 YYWLE	SEQ ID NO 17
CDRL2:		CDRH2:	
P YASESIS	SEQ ID NO 8	P EISPGTFTTNYNEKFKA	SEQ ID NO 18
#1 YAYESIS	SEQ ID NO 9	#1 EIEPGTFTTNYNEKFKA	SEQ ID NO 19
#2 YASESIY	SEQ ID NO 10	#2 EIDPGTFTTNYNEKFKA	SEQ ID NO 20
#3 YASESDS	SEQ ID NO 11	#3 EISPDFTTNYNEKFKA	SEQ ID NO 21
#4 YASESES	SEQ ID NO 12	#4 EISPETFTTNYNEKFKA	SEQ ID NO 22
CDRL3:		#5 EISPGTFETNYNEKFKA	SEQ ID NO 23
P QQSDSWPTT	SEQ ID NO 13	#6 EIEPGTFETNYNEKFKA	SEQ ID NO 24
#1 AASWSWPTT	SEQ ID NO 14	#7 EIDPGTFETNYNEKFKA	SEQ ID NO 25
		CDRH3:	
		P FSHFSGSNYDYFDY	SEQ ID NO 26
		#1 FSHFSGMNYDYFDY	SEQ ID NO 27
		#2 FSHFSGQNYDYFDY	SEQ ID NO 28
		#3 FSHFTGSNYDYFDY	SEQ ID NO 29

P = Parent

[0207] Nineteen heavy chain variants are presented in Figure 9 and 35 light chain variants are presented in Figure 8. Three candidates were further characterized for binding affinity and these are presented in Table 2.

TABLE 2 Binding Affinity

Mab	K <sub>D</sub>	Fold Increase in Binding Affinity
TES-C21	614 ± 200 pM	
MAb 1 (CL-5A)	0.158 pM	3886
MAb 2 (CL-2C)	1.47 ± 0.5 pM	417
MAb 3 (CL-5I)	3.2 ± 2.2 pM	191

### Example 11

#### Expression and purification of anti-IgE antibodies and HRP-conjugation

[0208] High affinity MAbs candidates were generated. For the generation of intact anti-IgE MAbs, the heavy and light chains variable regions were PCR amplified from phage vectors templates and subcloned separately into H- and L-chain expression vectors under the expression of a CMV promoter. Six full antibody clones were constructed and are represented in Figure 10 A-F. Appropriate heavy and light chain plasmids were co-transfected into the mouse myeloma cell line NS0 using electroporation by techniques well known in the art. See, e.g., Liou et al. J Immunol. 143(12):3967-75 (1989). Antibodies were purified from the single stable cell line supernatants using protein A-sepharose (Pharmacia). The concentration of the antibody was determined using spectrophotometer at 280nm and FCA assay (IDEXX).

[0209] Purified antibodies were conjugated by horseradish peroxidase (HRP) using peroxidase conjugation kit (Zymed Labs, San Francisco, CA) according to the manufacturer's protocol. The titer of each conjugated anti-IgE MAb was determined using ELISA with plates coated with a monoclonal human IgE (SE44).

[0210] The following cultures have been deposited with the American Type Culture Collection, 10801 University Boulevard, Manassas Va. 20110-2209 USA (ATCC):

Hybridoma	ATCC NO.	Deposit Date
Anti-IgE CL-2C	PTA-5678	December 3, 2003
Anti-IgE CL-5A	PTA-5679	December 3, 2003
Anti-IgE CL-5I	PTA-5680	December 3, 2003

[0211] This deposit was made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest Treaty). This assures maintenance of a viable culture for 30 years from the date of deposit. The organism will be made available by ATCC under the terms of the Budapest Treaty, which assures permanent and unrestricted availability of the progeny of the culture to the public upon issuance of the pertinent U.S. patent.

[0212] The assignee of the present application has agreed that if the culture on deposit should die or be lost or destroyed when cultivated under suitable conditions, it will be promptly replaced on notification with a viable specimen of the same culture. Availability of the deposited strain is not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any government in accordance with its patent laws.

[0213] The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by the cultures deposited, since the deposited embodiments are intended as illustration of one aspect of the invention and any culture that are functionally equivalent are within the scope of this invention. The deposit of material herein does not constitute an admission that the written description herein contained is inadequate to enable the practice of any aspect of the invention, including the best mode thereof, nor is it to be construed as limiting the scope of the claims to the specific illustration that it represents. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims.

## Example 12

### Mapping of the High Affinity Binding Epitope of Human IgE

#### A. Peptide synthesis and anti-IgE binding assay

[0214] Studies have shown that IgE binds to its receptor through the C<sub>H</sub>3 domain. Since the HA Anti-IgE antibodies of the present invention very efficiently block IgE from binding to its receptor, we mapped the epitope using peptides that encompassed the entire CH3 domain. First, we prepared two V5-tagged peptides, one comprised the entire constant region of human IgE and one comprised just the C<sub>H</sub>2-C<sub>H</sub>3 region of human IgE. These two peptides were expressed by *in vitro* transcription-translation and used in a Western blot assay to detect HA Anti-IgE MAb binding. Both CL-2C and CL-5I MAbs were able to bind to the intact human IgE as well as both the peptides.

[0215] To map the epitope more specifically, 73 overlapping peptides were synthesized which encompassed amino acid residues 141 to 368 of human IgE, which included the entire C<sub>H</sub>3 domain. Each peptide consisted of 12 amino acid residues having a 3 amino acid overlap with the 3' end of the previous peptide. SPOTs membranes were synthesized with fluorenylmethoxycarbonyl (Fmoc) amino acids on cellulose membrane. The membranes were rinsed in methanol and then washed in TBS (pH 7.5) 3X for 10 min. After an overnight incubation in blocking solution (5% milk or 3% BSA in TBS), HRP-labeled anti-IgE MAbs diluted in blocking solution were incubated with the membrane for 3 hrs. After washing 3X for 15 min in TBS-TWEEN<sup>®</sup>, using SuperSignal HRP substrate (Pierce), IgE reactivity was measured by chemiluminescence exposure of BioMax MS film (Kodak) for the desired time.

[0216] The results from the experiment indicate that the HA Anti-IgE MAbs bind to two regions in the C<sub>H</sub>3 portion of IgE, which are represented by the following two peptide sequences: NPRGVSA<sup>Y</sup>LSRP (epitope "A") and HPHLPRALMRST (Epitope "B"). (See Figure 12.) Binding to epitope A was several times weaker than to epitope B.

#### B. Alanine Scan Mutagenesis

[0217] An alanine scan along with substitutions of amino acids in the peptides with those that are found in IgG1 was carried out to determine which amino acids are critically involved in HA Anti-IgE MAb's binding to these peptides. Amino acids

that were determined to be important for HA Anti-IgE MAb binding were replaced using an in vitro mutagenesis strategy in the  $\epsilon$  chain of IgE. Another peptide covering the C $\epsilon$ 2 and C $\epsilon$ 3 regions as described earlier was also used in this study. (See Figures 13 and 14).

[0218] The EU numbering scheme for human IgE amino acid residues has been used. Polymerase chain reaction (PCR) was used to amplify the entire Fc region of IgE, and a truncated form of IgE Fc containing only the CH2-CH3 domain. The DNA products were cloned directly into pcDNA3 expression vector (Invitrogene, Carlsbad, CA) using TOPO cloning (Invitrogene, Carlsbad, CA).

[0219] Mutagenesis in IgE-Fc was performed using overlapping PCR (Ho et al., 1989). The DNA products were purified by agarose gel electrophoresis, digested with an appropriate restriction enzyme(s), and subcloned into the pcDNA3 expression vector. For each variant construct, PCR amplified regions were completely sequenced using dideoxynucleotide method from both strands of DNA. Recombinant human IgE Fc and its mutants were expressed using reticulocyte lysate based in-vitro transcription and translation coupled system (Promega, Madison, WI)

[0220] Lysates from this in-vitro transcription and translation coupled system (10 ul reaction mix) were subjected to SDS-PAGE (12 %) and then transferred to nitrocellulalose membranes. The membranes were blocked with 5% dry milk in Tris-buffered saline (TBS) and subsequently stained with the primary antibody, anti-IgE MAbs. Specific reactive bands were detected using a goat anti-human IgG Fc conjugated to horseradish peroxidase (Jackson Labs, Bar Harbor, Maine) and the immunoreactive bands were visualized by the SuperSignal Western blotting detection kit (Pierce). Anti-V5 antibodies were used as a positive control that detected the V5 tag introduced at the C-terminus of these peptides. The Western blot with anti-V5 antibodies demonstrated that all the peptides were expressed at almost equal level. Interestingly, HA Anti-IgE MAbs were able to bind to the peptide that carried mutations in epitope 'A', but, they did not bind to the peptide that carried mutations in epitope 'B', indicating that this second site was more important for binding. (See Figure 15).



### Example 13

#### Active Immunization of Transgenic Mice Using an Immunogenic Peptide of Epitope B

[0221] Transgenic mice that constitutively express human IgE were used to demonstrate the active production of antibodies to a human immunogenic peptide of Epitope B. Two fusion peptides, each comprising an immunogenic peptide of the invention, a cysteine residue and KLH, were chemically synthesized. The sequence of peptide 1 was :

(KLH-Cys) - Leu Pro Arg Ala Leu Met Arg Ser Thr

and the sequence of peptide 2 was:

Leu Pro Arg Ala Leu Met Arg Ser Thr – (Cys-KLH)

[0222] The transgenic mice were injected subcutaneously with 20  $\mu\text{g}$  of the immunogenic peptide in complete Freund's adjuvant (Difco Laboratories, Detroit, MI) in 200  $\mu\text{L}$  of PBS pH 7.4. At two-week intervals the mice were twice injected subcutaneously with 20  $\mu\text{g}$  of the peptide immunogen in incomplete Freund's adjuvant. Then, two weeks later and three days prior to sacrifice, the mice were again injected intraperitoneally with 20  $\mu\text{g}$  of the same immunogen in PBS. Serum was collected and tested for the presence of anti-IgE antibodies specific for Epitope B. As seen in Figure 16, the peptide elicited anti-IgE antibodies in these transgenic mice.

[0223] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

## We Claim:

1. An isolated peptide consisting essentially of the amino acid sequence:  
Asn Pro Arg Gly Val Ser Xaa Tyr Xaa Xaa Arg Xaa (SEQ ID NO. 72).
2. The amino acid of claim 1, wherein the amino acid sequence is:  
Asn Pro Arg Gly Val Ser Ala Tyr Leu Ser Arg Pro (SEQ ID NO. 73).
3. An isolated peptide consisting essentially of the amino acid sequence:  
Leu Pro Arg Ala Leu Xaa Arg Ser Xaa (SEQ ID NO: 74).
4. The peptide of claim 3, wherein the amino acid sequence is:
  - a) Leu Pro Arg Ala Leu Met Arg Ser Thr (SEQ ID NO: 75)
  - b) Hi Pro His Leu Pro Arg Ala Leu Met Arg Ser Thr (SEQ ID NO: 76); or
  - c) Leu Pro Arg Ala Leu Met Arg Ser Thr Thr Lys Thr (SEQ ID NO:77).
5. A composition comprising the peptide of claim 1 or claim 3 and a physiologically acceptable carrier, diluent, stabilizer or excipient.
6. The composition of claim 5, further comprising an immunogenic carrier.
7. The composition of claim 6, wherein the immunogenic carrier is selected from the group consisting of BSA, KLH, tetanus toxoid, and diphtheria toxoid.
8. An isolated antibody that specifically binds to the peptide of any one of claims 1 to 4.
9. The antibody of claim 8, further comprising a label.
10. The antibody of claim 8, wherein the antibody is:
  - a) a chimeric antibody,
  - b) a single chain antibody,
  - c) a Fab fragment,
  - d) a F(ab'), fragment,
  - e) a human antibody, or
  - f) a humanized antibody.
11. A composition comprising an antibody of claim 8 and an acceptable carrier.
12. A method preparing a polyclonal antibody, the method comprising:
  - a) immunizing an animal with a polypeptide consisting of an amino acid

- sequence of SEQ ID NO:72 or SEQ ID NO:74 under conditions to elicit an antibody response,
- b) isolating antibodies from the animal, and
  - c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which specifically binds with high affinity to a polypeptide comprising an amino acid sequence of SEQ ID NO:72 or SEQ ID NO:74.
13. A polyclonal antibody produced by a method of claim 12.
  14. A composition comprising the polyclonal antibody of claim 13 and a suitable carrier.
  15. A method of making a monoclonal antibody, the method comprising:
    - a) immunizing an animal with a polypeptide consisting essentially of an amino acid sequence of SEQ ID NO:72 or SEQ ID NO:74 under conditions to elicit an antibody response,
    - b) isolating antibody producing cells from the animal,
    - c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells,
    - d) culturing the hybridoma cells, and
    - e) isolating from the culture a monoclonal antibody which specifically binds with high affinity to a polypeptide comprising an amino acid sequence of SEQ ID NO:72 or SEQ ID NO:74.
  16. A monoclonal antibody produced by a method of claim 15.
  17. A composition comprising the monoclonal antibody of claim 16 and a suitable carrier.
  18. The antibody of claim 8, wherein the antibody is produced by screening a Fab expression library.
  19. The antibody of claim 8, wherein the antibody is produced by screening a combinatorial immunoglobulin library.
  20. A kit comprising the antibody of any one of claims 8-19.
  21. A method of inducing an immunological response to IgE in a mammal comprising administering the peptide or the composition of any one of claims 1-7, in an amount sufficient to induce a response in said mammal.

**Figure 1 Phage Vector**





FIGURE 2



**Figure 3 TES-C21 and Template Comparison**

**A. Light Chain (V<sub>K</sub>)** (Underlined: Kabat CDR. Bold/Italic: Chothia CDR) (TES-C21 LIGHT CHAIN - SEQ ID NO 1 L16/JK4 - SEQ ID NO2)

Mu TES-C21 D I L L T Q S P A I L S V S P G E R V S F S C R A S Q S I G T N I H W Y Q Q  
 L16 VK E V M T A T L R A S Q S V S S N L A

10 20 30 70

TES-C21 R T D G S P R L L I K Y A S E S I S G I P S R F S G S G S G T E F T L N I N  
 L16 VK K P G Q A Y G A S T R A T A

40 50 60 70

TES-C21 S V E S E D I A D Y Y C Q Q S D S W P T T F G G G T K L E I K  
 L16 VK-JK4 L Q F V Q Q Y N N W P L T

80 90 100 107

**B. Heavy Chain (V<sub>H</sub>)**  
 TES-C21 HEAVY CHAIN - SEQ ID NO 3 DP88/JH4b - SEQ ID NO 4

Murine TES-C21 Q V Q L Q Q S G A E L M K P G A S V K I S C K T T G Y T F S M Y W L E W V  
 DP88 VH V V K S V V A S G S Y A I S

1 10 20 30

TES-C21 K Q R P G H G L E W V G E I S P G T F T T N Y N E K F K A K A T F T A D T  
 DP88 VH R A Q M G I I P I F G T A N Y A Q K F Q G R V I K

40 50 52a 53 60 65 70

TES-C21 S S N T A Y L Q L S G L T S E D S A V Y F C A R F S H F S G S N Y D Y F D Y  
 DP88 VH T S M E S R T Y - - - - - Y F D Y

80 82a b c 83 90 95 100 b c d e f 101

TES-C21 W G Q G T S L T V S S  
 DP88-JH4b L V

103 110 113


**Figure 4 Framework Sequences of High Affinity Candidates\***

VK Positions	1	3	4	49	60	85	VH Positions	12	27	43	48	67	69
Mouse	D	L	L	K	S	D	Mouse	M	Y	H	V	A	F
Human	E	V	M	Y	A	V	Human	K	G	Q	M	V	I
1 (clone ID)	D	L	M	K	S	V	M	Y	H	M	A	F	
2	D	V	L	K	A	V	K	Y	Q	M	V	F	
4	D	L	L	Y	S	V	M	Y	Q	M	V	F	
8	D	V	M	Y	S	V	M	Y	Q	M	A	F	
13	E	V	L	K	A	D	K	Y	Q	M	A	F	
15	D	L	M	Y	A	V	M	Y	Q	V	V	F	
16	D	L	M	Y	A	V	M	Y	Q	M	V	F	
18	E	L	L	K	S	D	M	Y	Q	M	V	F	
21	D	V	L	Y	A	V	M	Y	H	V	V	F	
23	D	L	L	K	A	D	M	Y	Q	M	V	F	
25	E	V	M	Y	A	V	M	Y	Q	V	A	F	
27	E	L	M	Y	S	D	M	Y	Q	V	V	F	
30	E	V	L	Y	A	D	K	Y	Q	V	V	F	
31	E	V	L	Y	A	V	M	Y	H	V	A	F	
33	E	V	L	Y	S	V	K	Y	Q	M	V	F	
35	E	V	M	Y	A	D	K	Y	H	M	V	F	
38	E	V	M	K	A	D	K	Y	Q	M	V	F	
43	E	V	L	Y	S	V	M	Y	H	M	V	I	
44	E	V	L	Y	A	D	M	Y	H	V	V	I	
45	E	V	M	K	A	V	M	Y	Q	M	V	F	
46	E	V	L	K	S	V	M	Y	H	V	V	F	
48	E	V	M	Y	A	D	M	Y	H	V	V	F	
49	E	V	M	Y	A	V	M	Y	Q	M	V	F	
50	D	L	L	Y	A	D	M	Y	H	V	A	F	
52	E	L	L	Y	A	D	K	Y	Q	V	V	F	
53	D	V	L	Y	S	V	M	Y	H	M	V	F	
56	D	L	M	Y	S	V	M	Y	H	M	A	F	
58	D	V	M	K	S	V	M	Y	H	M	V	F	
61	D	V	M	K	S	V	M	Y	H	M	V	F	
63	D	V	M	K	S	V	K	Y	Q	V	V	F	
64	E	V	M	K	S	D	M	Y	Q	V	V	F	
68	D	V	L	Y	S	V	M	Y	Q	V	V	F	
70	D	V	L	Y	A	D	K	Y	Q	M	A	F	
72	D	V	L	Y	A	V	M	Y	H	M	V	F	
75	E	L	L	K	S	V	K	Y	Q	M	A	F	
76	D	V	M	Y	S	V	M	Y	Q	M	V	F	
78	D	V	M	Y	S	V	M	Y	Q	M	V	F	
81	E	V	L	K	S	D	M	Y	Q	M	A	F	
83	E	V	L	K	A	D	M	Y	H	V	V	F	
86	E	L	M	K	A	V	M	Y	Q	M	V	F	
89	E	L	M	Y	A	V	M	Y	H	V	V	F	
90	D	V	M	Y	A	D	K	Y	H	V	V	F	
93	E	L	M	K	A	V	M	Y	Q	V	A	F	
103	D	V	L	Y	A	V	M	Y	Q	V	A	I	
109	D	L	L	K	S	V	M	Y	H	V	A	F	
114	D	L	L	Y	A	V	M	Y	Q	V	V	F	
124	E	V	L	Y	S	D	K	Y	Q	V	V	F	
126	D	V	M	Y	A	V	M	Y	Q	V	V	F	
135	D	V	L	K	S	V	M	Y	Q	M	V	F	
136	E	V	M	Y	A	V	M	Y	H	M	V	F	
152	E	V	L	Y	S	V	M	Y	H	V	V	F	
153	D	L	L	Y	S	V	K	Y	Q	M	V	F	
157	D	L	M	Y	S	D	K	Y	Q	M	V	F	
1136-2C	E	V	M	Y	S	D	K	Y	Q	M	V	F	

\*P=parent sequence; T=human template sequence; amino acids listed in bold are murine residues

**Figure 5 ELISA TITRATION CURVE**

**A**



**B**






Figure 6 Inhibition Assay




Figure 7: List of High Affinity Candidates from Library

Clone	CDR-L1	CDR-L2	CDR-L3	CDR-H1	CDR-H2	CDR-H3
136	RASRSIG	YASES	QQSASW	MYWLE	EISPGTFTTNYNEKF	FSHFSGSNYDY
L3-9	wt	wt	QQSWSW	wt	wt	wt
CL-2	wt	wt	QQSWSW	<b>WYWLE</b>	wt	wt
R5-E	wt	wt	QQSWSW	<b>YYWLE</b>	wt	wt
R87-J	wt	wt	QQSWSW	wt	<b>EIEPGTFTTNYNEKF</b>	wt
CL-2	wt	wt	QQSWSW	wt	<b>EIDPGTFTTNYNEKF</b>	wt
R2-C	wt	wt	QQSWSW	<b>WYWLE</b>	<b>EIEPGTFTTNYNEKF</b>	wt
CL-2	wt	wt	QQSWSW	<b>WYWLE</b>	<b>EIDPGTFTTNYNEKF</b>	wt
CL-2	wt	wt	QQSWSW	<b>YYWLE</b>	<b>EIEPGTFTTNYNEKF</b>	wt
CL-2	wt	wt	QQSWSW	<b>YYWLE</b>	<b>EIDPGTFTTNYNEKF</b>	wt
CL-3	wt	wt	QQSWSW	wt	<b>EISPETFTTNYNEKF</b>	wt
R47-J	wt	wt	QQSWSW	wt	<b>EISPDFTTNYNEKF</b>	wt
CL-3	wt	wt	QQSWSW	<b>YYWLE</b>	<b>EISPETFTTNYNEKF</b>	wt
R3-A	wt	wt	QQSWSW	<b>YYWLE</b>	<b>EISPDFTTNYNEKF</b>	wt
CL-3	wt	wt	QQSWSW	<b>WYWLE</b>	<b>EISPETFTTNYNEKF</b>	wt
CL-3	wt	wt	QQSWSW	<b>WYWLE</b>	<b>EISPDFTTNYNEKF</b>	wt
R5-K	wt	wt	QQSWSW	wt	<b>EISPGTFETNYNEKF</b>	wt
CL-4	wt	wt	QQSWSW	<b>WYWLE</b>	<b>EISPGTFETNYNEKF</b>	wt
R5-D	wt	wt	QQSWSW	<b>YYWLE</b>	<b>EISPGTFETNYNEKF</b>	wt
CL-5	wt	wt	QQSWSW	wt	<b>EIEPGTFETNYNEKF</b>	wt
CL-5	wt	wt	QQSWSW	wt	<b>EIDPGTFETNYNEKF</b>	wt
CL-5	wt	wt	QQSWSW	<b>WYWLE</b>	<b>EIEPGTFETNYNEKF</b>	wt
CL-5	wt	wt	QQSWSW	<b>WYWLE</b>	<b>EIDPGTFETNYNEKF</b>	wt
R5-H	wt	wt	QQSWSW	<b>YYWLE</b>	<b>EIEPGTFETNYNEKF</b>	wt
R5-N	wt	wt	QQSWSW	<b>YYWLE</b>	<b>EIDPGTFETNYNEKF</b>	wt

Changes from parent amino acid sequence are listed in **BOLD**.

FIGURE 8A

VK Alignment																						SEQ ID			SEQ ID																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																	
		1	2	3	4	5	6	7	8	9	#	#	#	#	#	#	#	#	#	#	#	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143	144	145	146	147	148	149	150	151	152	153	154	155	156	157	158	159	160	161	162	163	164	165	166	167	168	169	170	171	172	173	174	175	176	177	178	179	180	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200	201	202	203	204	205	206	207	208	209	210	211	212	213	214	215	216	217	218	219	220	221	222	223	224	225	226	227	228	229	230	231	232	233	234	235	236	237	238	239	240	241	242	243	244	245	246	247	248	249	250	251	252	253	254	255	256	257	258	259	260	261	262	263	264	265	266	267	268	269	270	271	272	273	274	275	276	277	278	279	280	281	282	283	284	285	286	287	288	289	290	291	292	293	294	295	296	297	298	299	300	301	302	303	304	305	306	307	308	309	310	311	312	313	314	315	316	317	318	319	320	321	322	323	324	325	326	327	328	329	330	331	332	333	334	335	336	337	338	339	340	341	342	343	344	345	346	347	348	349	350	351	352	353	354	355	356	357	358	359	360	361	362	363	364	365	366	367	368	369	370	371	372	373	374	375	376	377	378	379	380	381	382	383	384	385	386	387	388	389	390	391	392	393	394	395	396	397	398	399	400	401	402	403	404	405	406	407	408	409	410	411	412	413	414	415	416	417	418	419	420	421	422	423	424	425	426	427	428	429	430	431	432	433	434	435	436	437	438	439	440	441	442	443	444	445	446	447	448	449	450	451	452	453	454	455	456	457	458	459	460	461	462	463	464	465	466	467	468	469	470	471	472	473	474	475	476	477	478	479	480	481	482	483	484	485	486	487	488	489	490	491	492	493	494	495	496	497	498	499	500	501	502	503	504	505	506	507	508	509	510	511	512	513	514	515	516	517	518	519	520	521	522	523	524	525	526	527	528	529	530	531	532	533	534	535	536	537	538	539	540	541	542	543	544	545	546	547	548	549	550	551	552	553	554	555	556	557	558	559	560	561	562	563	564	565	566	567	568	569	570	571	572	573	574	575	576	577	578	579	580	581	582	583	584	585	586	587	588	589	590	591	592	593	594	595	596	597	598	599	600	601	602	603	604	605	606	607	608	609	610	611	612	613	614	615	616	617	618	619	620	621	622	623	624	625	626	627	628	629	630	631	632	633	634	635	636	637	638	639	640	641	642	643	644	645	646	647	648	649	650	651	652	653	654	655	656	657	658	659	660	661	662	663	664	665	666	667	668	669	670	671	672	673	674	675	676	677	678	679	680	681	682	683	684	685	686	687	688	689	690	691	692	693	694	695	696	697	698	699	700	701	702	703	704	705	706	707	708	709	710	711	712	713	714	715	716	717	718	719	720	721	722	723	724	725	726	727	728	729	730	731	732	733	734	735	736	737	738	739	740	741	742	743	744	745	746	747	748	749	750	751	752	753	754	755	756	757	758	759	760	761	762	763	764	765	766	767	768	769	770	771	772	773	774	775	776	777	778	779	780	781	782	783	784	785	786	787	788	789	790	791	792	793	794	795	796	797	798	799	800	801	802	803	804	805	806	807	808	809	810	811	812	813	814	815	816	817	818	819	820	821	822	823	824	825	826	827	828	829	830	831	832	833	834	835	836	837	838	839	840	841	842	843	844	845	846	847	848	849	850	851	852	853	854	855	856	857	858	859	860	861	862	863	864	865	866	867	868	869	870	871	872	873	874	875	876	877	878	879	880	881	882	883	884	885	886	887	888	889	890	891	892	893	894	895	896	897	898	899	900	901	902	903	904	905	906	907	908	909	910	911	912	913	914	915	916	917	918	919	920	921	922	923	924	925	926	927	928	929	930	931	932	933	934	935	936	937	938	939	940	941	942	943	944	945	946	947	948	949	950	951	952	953	954	955	956	957	958	959	960	961	962	963	964	965	966	967	968	969	970	971	972	973	974	975	976	977	978	979	980	981	982	983	984	985	986	987	988	989	990	991	992	993	994	995	996	997	998	999	1000







**Figure 10A Polypeptide sequence of Mab 136****LIGHT CHAIN****SIGNAL PEPTIDE**

MEWSGVFMFLLSVTAGVHS (SEQ ID NO 56)

**VARIABLE REGION Vk**EIVMTQSPAT LSVSPGERAT LSCRASQSIG TNIHWYQQKP GQAPRLLIYY  
ASESISGIPA RFSGSGSGTE FTLTISSLQS EDFAVYVCQQ SDSWPTTFGG  
GTKVEIK (SEQ ID NO 57)**CONSTANT REGION Ck**TVAAPSVFIF PPSDEQLKSG TASVVCLLNN FYPREAKVQW KVDNALQSGN  
SQESVTEQDS KDSTYLSLST LTLKADYK HKVYACEVTH QGLSSPVTKS  
FNRGEC (SEQ ID NO 58)**HEAVY CHAIN (IgG1)****SIGNAL PEPTIDE**

MEWSGVFMFLLSVTAGVHS (SEQ ID NO 56)

**VARIABLE REGION VH**QVQLVQSGAE VMKPGSSVKV SCKASGYTFS MYWLEWVRQA PGHGLEWMGE  
ISPGTFTTNY NEKFKARVTF TADTSTSTAY MELSSLRSED TAVYYCARFS  
HFSGSNYDYF DYWGQGTTLVT VSS (SEQ ID NO 59)**CONSTANT REGION CH1-3(IgG1) (SEQ ID NO 60)**ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSKV  
HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKEP  
KSCDKTHTCP PCPAPPELLGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS  
HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQQDLNKG  
EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE LTKNQVSLTC  
LVKGFYPSDI AVEWESNGQP ENNYKTTTPV LKSDGTSFLLY SKLTVDKSRW  
QQGNVFCFSV MHEALHNHYT QKSLSLSPGK

**Figure 10B Polypeptide Sequence of Mab CL-2C****LIGHT CHAIN****SIGNAL PEPTIDE**

MEWSGVFMFLLSVTAGVHS (SEQ ID NO 56)

**VARIABLE REGION Vk**EIVMTQSPAT LSVSPGERAT LSCRASQSIG TNIHWYQQKP GQAPRLLIYY  
ASESISGIPA RFSGSGSGTE FTLTSSLQS EDFAVYVCQQ SWSWPTTFGG  
GTKVEIK (SEQ ID NO 61)**CONSTANT REGION Ck**TVAAPSVFIF PPSDEQLKSG TASVVCLLNN FYPREAKVQW KVDNALQSGN  
SQESVTEQDS KDSTYLSLST LTLKADYK HKVYACEVTH QGLSSPVTKS  
FNRGEC (SEQ ID NO 58)**HEAVY CHAIN (IgG1)****SIGNAL PEPTIDE**

MEWSGVFMFLLSVTAGVHS (SEQ ID NO 56)

**VARIABLE REGION VH (2C)**QVQLVQSGAE VMKPGSSVKV SCKASGYTFS WYWLEWVRQA PGHGLEWMGE  
IDPGTFTTNY NEKFKARVTF TADTSTSTAY MELSSLRSED TAVYYCARFS  
HFSGSNYDYF DYWGQGTLLVT VSS (SEQ ID NO 62)**CONSTANT REGION CH1-3(IgG1) (SEQ ID NO 60)**ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSKV  
HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHNKPS NTKVDDKVEP  
KSCDKTHTCP PCPAPELLGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS  
HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK  
EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE LTKNQVSLTC  
LVKGFYPSDI AVEWESNGQP ENNYKTTTPV LDSDGSFFLY SKLTVDKSRW  
QQGNVFCSSV MHEALHNHYT QKSLSLSPGK



**Figure 10C Polypeptide Sequence of MAb CL-5I****LIGHT CHAIN****SIGNAL PEPTIDE**

MEWSGVFMFLLSVTAGVHS (SEQ ID NO 56)

**VARIABLE REGION Vk**EIVMTQSPAT LSVSPGERAT LSCRASQSIG TNIHWYQQKP GQAPRLLIYY  
ASESISGIPA RFGSGSGTE FTLTISSLQS EDFAVYYCQQ SWSWPTTFGG  
GTKVEIK (SEQ ID NO 63)**CONSTANT REGION Ck (SEQ ID NO 58)**TVAAPSVFIF PPSDEQLKSG TASVVCLLNN FYPREAKVQW KVDNALQSGN  
SQESVTEQDS KSTYLSST LTLKADYK HKVYACEVTH QGLSPVTKS  
FNRGEC**HEAVY CHAIN (IgG1)****SIGNAL PEPTIDE**

MEWSGVFMFLLSVTAGVHS (SEQ ID NO 56)

**VARIABLE REGION VH (5I)**QVQLVQSGAE VMKPGSSVKV SCKASGYTFS MYWLEWVRQA PGHGLEWMGE  
IDPGTFETNY NEKFKARVTF TADTSTSTAY MELSSLRSED TAVYYCARFS  
HFSGSNYDYF DYWGQGLVTVSS (SEQ ID NO 64)**CONSTANT REGION CH1-3(IgG1) (SEQ ID NO 60)**ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV  
HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHNKPS NTKVDKKEP  
KSCDKHTTCP PCPAPPELLGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS  
HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK  
EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE LTKNQVSLTC  
LVKGFYPSDI AVEWESNGQP ENNYKTTTPV LDSDGSFFLY SKLTVDKSRW  
QQGNVFSQSV MHEALHNHYT QKSLSLSPGK

**Figure 10D Polypeptide Sequence of MAb CL-5A****LIGHT CHAIN****SIGNAL PEPTIDE**

MEWSGVFMFLLSVTAGVHS (SEQ ID NO 56)

**VARIABLE REGION Vk**EIVMTQSPAT LSVSPGERAT LSCRASQSIG TNIHWYQQKP GQAPRLLIYY  
ASESISGIPA RFSGSGSGTE FTLTISSLQS EDFAVYYCQQ SWSWPTTFGG  
GTKVEIK (SEQ ID NO 65)**CONSTANT REGION Ck (SEQ ID NO 58)**TVAAPSVFIF PPSDEQLKSG TASVVCLLNN FYPREAKVQW KVDNALQSGN  
SQESVTEQDS KDSTYLSLST LTLKADYEK HKVYACEVTH QGLSSPVTKS  
FNRGEC**HEAVY CHAIN (IgG1)****SIGNAL PEPTIDE**

MEWSGVFMFLLSVTAGVHS (SEQ ID NO 56)

**VARIABLE REGION VH (5A)**QVQLVQSGAE VMKPGSSVKV SCKASGYTFS WYWLEWVRQA PGHGLEWMGE  
IEPGTETNY NEKFKARVTF TADTSTSTAY MELSSLRSED TAVYYCARFS  
HFSGSNYDYF DYWGQGLVT VSS (SEQ ID NO 66)**CONSTANT REGION CH1-3(IgG1) (SEQ ID NO 60)**ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV  
HTFPVQLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP  
KSCDKTHTCP PCPAPELLGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS  
HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK  
EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE LTKNQVSLTC  
LVKGFYPSDI AVEWESNGQP ENNYKTTTPV LQSDGSEFFLY SKLTVDKSRW  
QQGNVFCFSV MHEALHNHYT QKSLSLSPGK

**Figure 10E Polypeptide Sequence of MAb CL-2B****LIGHT CHAIN****SIGNAL PEPTIDE**

MEWSGVFMFLLSVTAGVHS (SEQ ID NO 56)

**VARIABLE REGION Vk**EIVMTQSPAT LSVSPGERAT LSCRASQSIG TNIHWYQQKP GQAPRLLIYY  
ASESISGIPA RFSGSGSGTE FTLTISSLQS EDFAVYYCQQ SWSWPTTFGG  
GTKVEIK (SEQ ID NO 67)**CONSTANT REGION Ck (SEQ ID NO 58)**TVAAPSVFIF PPSDEQLKSG TASVVCLLNN FYPREAKVQW KVDNALQSGN  
SQESVTEQDS KDSTYLSST LTLKADYK HKVYACEVTH QGLSSPVTKS  
FNRGEC**HEAVY CHAIN (IgG1)****SIGNAL PEPTIDE**

MEWSGVFMFLLSVTAGVHS (SEQ ID NO 56)

**VARIABLE REGION VH (2B)**QVQLVQSGAE VMKPGSSVKV SCKASGYTFS YYWLEWVRQA PGHGLEWMGE  
IDPGTFTTNY NEKFKARVTF TADTSTSTAY MELSSLRSED TAVYYCARFS  
HFSGSNYDYF DYWGQGTLLVTVSS (SEQ ID NO 68)**CONSTANT REGION CH1-3(IgG1) (SEQ ID NO 60)**ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV  
HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHNKPS NTKVDDKVEP  
KSCDKTHTCP PCPAPPELLGG PSVFLFPPKP KDTLMISRTPEVTCVVVDVSD  
HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK  
EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE LTKNQVSLTCL  
LVKGFYPSDI AVEWESNGQP ENNYKTTTPPV LDSDGSFFLY SKLTVDKSRW  
QQGNVVFSCSV MHEALHNHYT QKSLSLSPGK

**Figure 10F Polypeptide Sequence of MAb CL-1136-2C****LIGHT CHAIN****SIGNAL PEPTIDE**

MEWSGVFMFLLSVTAGVHS (SEQ ID NO 56)

**VARIABLE REGION Vk**EIVMTQSPAT LSVSPGERAT LSCRASQSIG TNIHWYQQKP GQAPRLLIYY  
ASESISGIPA RFSGSGSGTE FTLTISSLQS EDFAVYYCQQ SWSWPTTFGG  
GTKVEIK (SEQ ID NO 69)**CONSTANT REGION Ck (SEQ ID NO 58)**TVAAPSVFIF PPSDEQLKSG TASVVCLLNN FYPREAKVQW KVDNALQSGN  
SQESVTEQDS KDSTYLSLST LTLKADYK HKVYACEVTH QGLSSPVTKS  
FNRGEC**HEAVY CHAIN (IgG1)****SIGNAL PEPTIDE**

MEWSGVFMFLLSVTAGVHS (SEQ ID NO 56)

**VARIABLE REGION (VH)**QVQLVQSGAE VKKPGSSVKV SCKASGYTFS WYWLEWVRQA PGQGLEWMGE  
ISPGTFTTNY NEKFKARVTF TADTSTSTAY MELSSLRSED TAVYYCARFS  
HFSGSNYDYF DYWGQGTLLVTVSS (SEQ ID NO 70)**CONSTANT REGION CH1-3(IgG1) (SEQ ID NO 60)**ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV  
HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKEP  
KSCDKHTHTCP PCPAPELLGG PSVFLFPPKP KDTLMISRTPEVTCVVVDVSD  
HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNQK  
EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE LTKNQVSLTCL  
LVKGFYPSDI AVEWESNGQP ENNYKTTTPV LKSDGTSFSTYLSKLTVDKSRW  
QQGNVVFSCSV MHEALHNHYT QKSLSLSPGK

Figure 11 – Amino Acid Sequence of the CH3 Domain of Human IgE

Nterminal - Asp Ser Asn Pro Arg Gly Val Ser Ala Tyr Leu Ser Arg Pro Ser Pro Phe Asp Leu

**Epitope A**

Phe Ile Arg Lys Ser Pro Thr IleThr Cys Leu Val Val Asp Leu Ala Pro Ser Lys Gly Thr Val Asn Leu

Thr Trp Ser Arg Ala Ser Gly Lys Pro Val Asn His Ser Thr Arg Lys Glu Glu Lys Gln Arg Asn Gly Thr

Leu Thr Val Thr Ser Thr Leu Pro Val Gly Thr Arg Asp Trp Ile Glu Gly Glu Thr Tyr Gln Cys Arg Val

Thr His Pro His Leu Pro Arg Ala Leu Met Arg Ser Thr Thr Lys Thr Ser (SEQ ID NO 71)

**Epitope B**

# Figure 12: Peptide Scan of Epitope B

## Ab binding


## Peptide sequence

53	YQCRVTHPHLPR	-
54	RVTHPHLPRALM	++
55	HPHLPRALMRST	+++
56	LPRALMRSTTKT	+++
57	ALMRSTTKTSGP	-

Consensus      LPRALMRST


## FIGURE 13 : ALANINE SCAN OF EPITOPE A

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

A  
B  
C  
D  
E  
F

Position of peptide in membrane	Peptide sequence	Residue substitution	Anti-IgE Ab Binding signal
A1	<b>N</b> PRGVSAYLSRP	WT	++
A2	<b>a</b> PRGVSAYLSRP	1N→A	++
A3	<b>N</b> aRGVSAYLSRP	2P→A	++
A4	<b>N</b> P <b>a</b> GVSAYLSRP	3R→A	-
A5	<b>N</b> PR <b>a</b> V <b>S</b> AYLSRP	4G→A	+++
A6	<b>N</b> PRG <b>a</b> SAYLSRP	5V→A	-
A7	<b>N</b> PRGV <b>a</b> AYLSRP	6S→A	++
A8	<b>N</b> PRGVSAYLSRP	WT	++
A9	<b>N</b> PRGV <b>S</b> a <b>a</b> LSRP	8Y→A	-
A10	<b>N</b> PRGV <b>S</b> AY <b>a</b> SRP	9L→A	+
A11	<b>N</b> PRGV <b>S</b> AYL <b>a</b> RP	10S→A	++
A12	<b>N</b> PRGV <b>S</b> AYLS <b>a</b> P	11R→A	-
A13	<b>N</b> PRGV <b>S</b> AYLS <b>R</b> a	12P→A	+++
A14	<b>N</b> a <b>e</b> G <b>a</b> SAYLSRP	2P→A,3R→E,5V→A	-
A15	<b>N</b> P <b>e</b> GVSAYLSRP	3R→E	-
A16	<b>N</b> PRGVSAYLSRP	WT	++
A17	<b>l</b> l <b>g</b> G <b>p</b> S <b>v</b> f <b>l</b> f <b>R</b> P	IgG1	-
A18	<b>l</b> PRGV <b>S</b> AYLSRP	1N→L	+++
A19	<b>N</b> l <b>R</b> GV <b>S</b> AYLSRP	2P→L	++
A20	<b>N</b> P <b>g</b> GV <b>S</b> AYLSRP	3R→G	-
B1	<b>N</b> PRG <b>p</b> SAYLSRP	5V→P	+
B2	<b>N</b> PRGV <b>S</b> v <b>Y</b> LSRP	7A→V	++
B3	<b>N</b> PRGV <b>S</b> A <b>f</b> LSRP	8Y→F	+
B4	<b>N</b> PRGV <b>S</b> AYL <b>f</b> RP	10S→F	++


FIGURE 14 : ALANINE SCAN OF EPITOPE B




Position of Peptide in membrane	Peptide Sequence	Residue Substitution	Anti-IgE Ab Binding Signal
B5	HPHLPRALMRST	WT	+++
B6	aPHLPRALMRST	1H→A	+++
B7	HaHLPRALMRST	2P→A	+++
B8	HPaLPRALMRST	3H→A	+++
B9	HPHaPRALMRST	4L→A	++
B10	HPHLaRALMRST	5P→A	+
B11	HPHLPaALMRST	6R→A	-
B12	HPHLPRALMRST	WT	+++
B13	HPHLPRaMRST	8L→A	+
B14	HPHLPRALaRST	9M→A	+++
B15	HPHLPRALMaST	10R→A	+
B16	HPHLPRALMRaT	11S→A	+++
B17	HPHLPRALMRSa	12T→A	+++
B18	HPHLPRALMRST	WT	+++
B19	HkaLPapiekti	IgG1	-
B20	HkHLPRALMRST	2P→K	+++
C1	HPHLPRpLMRST	7A→P	-
C2	HPHLPRAlMRST	8L→I	+++
C3	HPHLPRALeRST	9M→E	+
C4	HPHLPRALMkST	10R→K	++
C5	HPHLPRALMRtT	11S→T	+++
C6	HPHLPRALMRSi	12T→I	+++
C7	HPaLaeALMRST	3H→A, 5P→A, 6R→E	-
C8	HPHLPeALMRST	6R→E	-



Figure 15: WESTERN BLOT ANALYSIS



**FIGURE 16** Anti-IgE Response in Transgenic mice



IN THE UNITED STATES RECEIVING OFFICE FOR THE PCT

Applicant: Tanox, Inc. et al.

PCT Application Claiming Priority to PCT/US04/02892 and PCT/US04/02894

International Filing Date: 29 JULY 2004

For: IDENTIFICATION OF NOVEL IgE EPITOPES


Dear Sirs:

**STATEMENT REGARDING SEQUENCE LISTING**

Applicants hereby state that the Sequence Listing contains 77 amino acid sequences appearing in the specification, figures and claims. This Sequence Listing does not introduce any new matter and does not go beyond the disclosure as originally filed. Applicants also state that the information recorded on the computer readable disks is identical to the written Sequence Listing attached herewith.

Respectfully Submitted,

Dated: 29 Jul 2004.

BY:   
Cheryl A. Liljestrand  
Reg. No. 45,275

## SEQUENCE LISTING

<110> TANOX, INC.  
SINGH, Sanjaya  
HUANG, Danyang  
FUNG, Sek Chung

<120> Identification of Unique, High Affinity IgE Epitopes

<130> TNX-1030

<150> PCT/US04/02892  
<151> 2004-02-02

<150> PCT/US04/02894  
<151> 2004-02-02

<160> 77

<170> PatentIn version 3.2

<210> 1  
<211> 107  
<212> PRT  
<213> Murine

<220>  
<221> misc\_feature  
<223> TES-C21 LIGHT CHAIN

<400> 1

Asp Ile Leu Leu Thr Gln Ser Pro Ala Ile Leu Ser Val Ser Pro Gly  
1 5 10 15

Glu Arg Val Ser Phe Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn  
20 25 30

Ile His Trp Tyr Gln Gln Arg Thr Asp Gly Ser Pro Arg Leu Leu Ile  
35 40 45

Lys Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Asn Ile Asn Ser Val Glu Ser  
65 70 75 80

Glu Asp Ile Ala Asp Tyr Tyr Cys Gln Gln Ser Asp Ser Trp Pro Thr  
85 90 95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys  
100 105

<210> 2  
<211> 107  
<212> PRT  
<213> Human

<220>  
<221> misc\_feature

<223> L16/-JK4 human light chain consensus sequence template

<400> 2

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly  
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn  
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile  
35 40 45

Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser  
65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Leu  
85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys  
100 105

<210> 3

<211> 123

<212> PRT

<213> MURINE

<220>

<221> misc\_feature

<223> TES-C21 Heavy Chain

<400> 3

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Met Lys Pro Gly Ala  
1 5 10 15

Ser Val Lys Ile Ser Cys Lys Thr Thr Gly Tyr Thr Phe Ser Met Tyr  
20 25 30

Trp Leu Glu Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Val  
35 40 45

Gly Glu Ile Ser Pro Gly Thr Phe Thr Thr Asn Tyr Asn Glu Lys Phe  
50 55 60

Lys Ala Lys Ala Thr Phe Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr  
65 70 75 80

Leu Gln Leu Ser Gly Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys  
85 90 95

Ala Arg Phe Ser His Phe Ser Gly Ser Asn Tyr Asp Tyr Phe Asp Tyr  
Page 2

100

105

110

Trp Gly Gln Gly Thr Ser Leu Thr Val Ser Ser  
 115 120

<210> 4  
 <211> 113  
 <212> PRT  
 <213> Human

<220>  
 <221> misc\_feature  
 <223> DP88/JH4b human heavy chain consensus sequence template  
 <400> 4

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser  
 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr  
 20 25 30

Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met  
 35 40 45

Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe  
 50 55 60

Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr  
 65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

Ala Arg Tyr Phe Asp Tyr Leu Val Gln Gly Thr Ser Leu Thr Val Ser  
 100 105 110

Ser

<210> 5  
 <211> 11  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> TES-C21 CDRL1 SEQUENCE (TABLE 1)  
 <400> 5

Arg Ala Ser Gln Ser Ile Gly Thr Asn Ile His  
 1 5 10

<210> 6  
 <211> 11  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
<223> CDRL1 VARIANT SEQUENCE #1 (TABLE 1)  
<400> 6  
Arg Ala Ser Arg Ser Ile Gly Thr Asn Ile His  
1 5 10

<210> 7  
<211> 11  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> CDRL1 VARIANT SEQUENCE #2 (TABLE 1)  
<400> 7

Arg Ala Ser Gln Arg Ile Gly Thr Asn Ile His  
1 5 10

<210> 8  
<211> 7  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> TES-C21 CDRL2 SEQUENCE (TABLE 1)  
<400> 8

Tyr Ala Ser Glu Ser Ile Ser  
1 5

<210> 9  
<211> 7  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> CDRL2 VARIANT #1 (TABLE 1)  
<400> 9

Tyr Ala Tyr Glu Ser Ile Ser  
1 5

<210> 10  
<211> 7  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> CDRL2 VARIANT #2 (TABLE 1)  
<400> 10

Tyr Ala Ser Glu Ser Ile Tyr  
1 5

<210> 11  
<211> 7  
<212> PRT

<213> ARTIFICIAL

<220>

<223> CDRL2 VARIANT #3 (TABLE 1)

<400> 11

Tyr Ala Ser Glu Ser Asp Ser  
1 5

<210> 12

<211> 7

<212> PRT

<213> ARTIFICIAL

<220>

<223> CDRL2 VARIANT #4 (TABLE 1)

<400> 12

Tyr Ala Ser Glu Ser Glu Ser  
1 5

<210> 13

<211> 9

<212> PRT

<213> ARTIFICIAL

<220>

<223> TES-C21 CDRL3 (TABLE 1)

<400> 13

Gln Gln Ser Asp Ser Trp Pro Thr Thr  
1 5

<210> 14

<211> 9

<212> PRT

<213> ARTIFICIAL

<220>

<223> CDRL3 VARIANT (TABLE)

<400> 14

Ala Ala Ser Trp Ser Trp Pro Thr Thr  
1 5

<210> 15

<211> 5

<212> PRT

<213> ARTIFICIAL

<220>

<223> TES-C21 CDRH1

<400> 15

Met Tyr Trp Leu Glu  
1 5

<210> 16

<211> 5



<212> PRT  
<213> ARTIFICIAL

<220>  
<223> CDRH1 VARIANT #1 (TABLE 1)

<400> 16

Trp Tyr Trp Leu Glu  
1 5

<210> 17  
<211> 5  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> CDRH1 #2 (TABLE 1)

<400> 17

Tyr Tyr Trp Leu Glu  
1 5

<210> 18  
<211> 17  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> TES-C21 CDRH2 (TABLE 1)

<400> 18

Glu Ile Ser Pro Gly Thr Phe Thr Thr Asn Tyr Asn Glu Lys Phe Lys  
1 5 10 15

Ala

<210> 19  
<211> 17  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> CDRH2 VARIANT #1 (TABLE 1)

<400> 19

Glu Ile Glu Pro Gly Thr Phe Thr Thr Asn Tyr Asn Glu Lys Phe Lys  
1 5 10 15

Ala

<210> 20  
<211> 17  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> CDRH2 VARIANT #2 (TABLE 1)

&lt;400&gt; 20

Glu Ile Asp Pro Gly Thr Phe Thr Thr Asn Tyr Asn Glu Lys Phe Lys  
 1 5 10 15

Ala

<210> 21  
 <211> 17  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> CDRH2 VARIANT #3 (TABLE 1)

&lt;400&gt; 21

Glu Ile Ser Pro Asp Thr Phe Thr Thr Asn Tyr Asn Glu Lys Phe Lys  
 1 5 10 15

Ala

<210> 22  
 <211> 17  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> CDRH2 VARIANT #4 (TABLE 1)

&lt;400&gt; 22

Glu Ile Ser Pro Glu Thr Phe Thr Thr Asn Tyr Asn Glu Lys Phe Lys  
 1 5 10 15

Ala

<210> 23  
 <211> 17  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> CDRH2 VARIANT #5 (TABLE 1)

&lt;400&gt; 23

Glu Ile Ser Pro Gly Thr Phe Glu Thr Asn Tyr Asn Glu Lys Phe Lys  
 1 5 10 15

Ala

<210> 24  
 <211> 17  
 <212> PRT  
 <213> ARTIFICIAL

&lt;220&gt;

&lt;223&gt; CDRH2 VARIANT #6 (TABLE 1)

&lt;400&gt; 24

Glu Ile Glu Pro Gly Thr Phe Glu Thr Asn Tyr Asn Glu Lys Phe Lys  
 1 5 10 15

Ala

&lt;210&gt; 25

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; ARTIFICIAL

&lt;220&gt;

&lt;223&gt; CDRH2 VARIANT #7 (TABLE 1)

&lt;400&gt; 25

Glu Ile Asp Pro Gly Thr Phe Glu Thr Asn Tyr Asn Glu Lys Phe Lys  
 1 5 10 15

Ala

&lt;210&gt; 26

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; ARTIFICIAL

&lt;220&gt;

&lt;223&gt; TES-C21 CDRH3 (TABLE 1)

&lt;400&gt; 26

Phe Ser His Phe Ser Gly Ser Asn Tyr Asp Tyr Phe Asp Tyr  
 1 5 10

&lt;210&gt; 27

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; ARTIFICIAL

&lt;220&gt;

&lt;223&gt; CDRH3 VARIANT #1 (TABLE 1)

&lt;400&gt; 27

Phe ser His Phe Ser Gly Met Asn Tyr Asp Tyr Phe Asp Tyr  
 1 5 10

&lt;210&gt; 28

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; ARTIFICIAL

&lt;220&gt;

&lt;223&gt; CDRH3 VARIANT #2 (TABLE 1)

&lt;400&gt; 28

Phe Ser His Phe Ser Gly Gln Asn Tyr Asp Tyr Phe Asp Tyr  
 1 5 10

<210> 29  
 <211> 14  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> CDRH3 VARIANT #3 (TABLE 1)

<400> 29

Phe Ser His Phe Thr Gly Ser Asn Tyr Asp Tyr Phe Asp Tyr  
 1 5 10

<210> 30  
 <211> 23  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> FRL1 VARIANT 136

<400> 30

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly  
 1 5 10 15

Glu Arg Ala Thr Leu Ser Cys  
 20

<210> 31  
 <211> 23  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> FRL1 VARIANT 1

<400> 31

Asp Ile Leu Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly  
 1 5 10 15

Glu Arg Ala Thr Leu Ser Cys  
 20

<210> 32  
 <211> 23  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> FRL1 VARIANT 2

<400> 32

Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly  
 1 5 10 15

Glu Arg Ala Thr Leu Ser Cys  
20

<210> 33  
<211> 23  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> FRL1 VARIANT 4

<400> 33

Asp Ile Leu Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly  
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys  
20

<210> 34  
<211> 23  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> FRL1 VARIANT 13

<400> 34

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly  
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys  
20

<210> 35  
<211> 23  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> FRL1 VARIANT 18

<400> 35

Glu Ile Leu Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly  
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys  
20

<210> 36  
<211> 23  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> FRL1 VARIANT 25

<400> 36

Asp Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly  
Page 10

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys  
20

<210> 37  
<211> 23  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> FRL1 VARIANT 27

<400> 37

Glu Ile Leu Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly  
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys  
20

<210> 38  
<211> 15  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> FRL2 VARIANT 136

<400> 38

Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr  
1 5 10 15

<210> 39  
<211> 15  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> FRL2 VARIANT 1

<400> 39

Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Lys  
1 5 10 15

<210> 40  
<211> 32  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> FRL3 VARIANT 136

<400> 40

Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr  
1 5 10 15

Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys  
20 25 30

<210> 41  
 <211> 32  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> FRL3 VARIANT 1

<400> 41

Gly Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr  
 1 5 10 15

Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys  
 20 25 30

<210> 42  
 <211> 32  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> FRL3 VARIANT 13

<400> 42

Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr  
 1 5 10 15

Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Asp Tyr Tyr Cys  
 20 25 30

<210> 43  
 <211> 32  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> FRL3 VARIANT 18

<400> 43

Gly Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr  
 1 5 10 15

Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Asp Tyr Tyr Cys  
 20 25 30

<210> 44  
 <211> 10  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> FRL4 VARIANT

<400> 44

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys  
 1 5 10

<210> 45  
 <211> 30  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> FRH1 VARIANT 136

<400> 45

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Met Lys Pro Gly Ser  
 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser  
 20 25 30

<210> 46  
 <211> 30  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> FRH1 VARIANT 2

<400> 46

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser  
 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser  
 20 25 30

<210> 47  
 <211> 14  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> FRH2 VARIANT 136

<400> 47

Trp Val Arg Gln Ala Pro Gly His Gly Leu Glu Trp Met Gly  
 1 5 10

<210> 48  
 <211> 14  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> FRH2 VARIANT 2

<400> 48

Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly  
 1 5 10

<210> 49  
 <211> 14  
 <212> PRT  
 <213> ARTIFICIAL



&lt;220&gt;

&lt;223&gt; FRH2 VARIANT 8

&lt;400&gt; 49

Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Val Gly  
 1 5 10

&lt;210&gt; 50

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; ARTIFICIAL

&lt;220&gt;

&lt;223&gt; FRH2 VARIANT 21

&lt;400&gt; 50

Trp Val Arg Gln Ala Pro Gly His Gly Leu Glu Trp Val Gly  
 1 5 10

&lt;210&gt; 51

&lt;211&gt; 32

&lt;212&gt; PRT

&lt;213&gt; ARTIFICIAL

&lt;220&gt;

&lt;223&gt; FRH3 VARIANT 136

&lt;400&gt; 51

Arg Val Thr Phe Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr Met Glu  
 1 5 10 15

Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg  
 20 25 30

&lt;210&gt; 52

&lt;211&gt; 32

&lt;212&gt; PRT

&lt;213&gt; ARTIFICIAL

&lt;220&gt;

&lt;223&gt; FRH3 VARIANT 1

&lt;400&gt; 52

Arg Ala Thr Phe Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr Met Glu  
 1 5 10 15

Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg  
 20 25 30

&lt;210&gt; 53

&lt;211&gt; 32

&lt;212&gt; PRT

&lt;213&gt; ARTIFICIAL

&lt;220&gt;

&lt;223&gt; FRH3 VARIANT 43

&lt;400&gt; 53

Arg Val Thr Ile Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr Met Glu  
 1 5 10 15

Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg  
 20 25 30

<210> 54  
 <211> 32  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> FRH3 VARIANT 103

<400> 54

Arg Ala Thr Ile Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr Met Glu  
 1 5 10 15

Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg  
 20 25 30

<210> 55  
 <211> 11  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> FRH4 VARIANT 136

<400> 55

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser  
 1 5 10

<210> 56  
 <211> 19  
 <212> PRT  
 <213> Bacteriophage M13mp18

<220>  
 <221> misc\_feature  
 <223> Gene III signal Sequence

<400> 56

Met Glu Trp Ser Gly Val Phe Met Phe Leu Leu Ser Val Thr Ala Gly  
 1 5 10 15

Val His Ser

<210> 57  
 <211> 107  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> LIGHT CHAIN VARIABLE REGION OF CLONE 136

&lt;400&gt; 57

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly  
 1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn  
 20 25 30

Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile  
 35 40 45

Tyr Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Ala Arg Phe Ser Gly  
 50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser  
 65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Asp Ser Trp Pro Thr  
 85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys  
 100 105

&lt;210&gt; 58

&lt;211&gt; 106

&lt;212&gt; PRT

&lt;213&gt; ARTIFICIAL

&lt;220&gt;

&lt;223&gt; LIGHT CHAIN CONSTANT REGION OF CLONE 136

&lt;400&gt; 58

Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln  
 1 5 10 15

Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr  
 20 25 30

Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser  
 35 40 45

Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr  
 50 55 60

Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys  
 65 70 75 80

His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro  
 85 90 95

Val Thr Lys Ser Phe Asn Arg Gly Glu Cys  
 100 105

&lt;210&gt; 59

<211> 123  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> HEAVY CHAIN VARIABLE REGION OF CLONE 136

<400> 59

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Met Lys Pro Gly Ser  
 1 5 10 15  
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Met Tyr  
 20 25 30  
 Trp Leu Glu Trp Val Arg Gln Ala Pro Gly His Gly Leu Glu Trp Met  
 35 40 45  
 Gly Glu Ile Ser Pro Gly Thr Phe Thr Thr Asn Tyr Asn Glu Lys Phe  
 50 55 60  
 Lys Ala Arg Val Thr Phe Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr  
 65 70 75 80  
 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Ala Arg Phe Ser His Phe Ser Gly Ser Asn Tyr Asp Tyr Phe Asp Tyr  
 100 105 110  
 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser  
 115 120

<210> 60  
 <211> 330  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> CONSTANT REGION OF HUMAN IgG1

<400> 60

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys  
 1 5 10 15  
 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr  
 20 25 30  
 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser  
 35 40 45  
 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser  
 50 55 60  
 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr  
 65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys  
 85 90 95  
 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys  
 100 105 110  
 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro  
 115 120 125  
 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys  
 130 135 140  
 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp  
 145 150 155 160  
 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu  
 165 170 175  
 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu  
 180 185 190  
 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn  
 195 200 205  
 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly  
 210 215 220  
 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu  
 225 230 235 240  
 Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr  
 245 250 255  
 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn  
 260 265 270  
 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe  
 275 280 285  
 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn  
 290 295 300  
 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr  
 305 310 315 320  
 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys  
 325 330

<210> 61  
 <211> 107  
 <212> PRT

<213> ARTIFICIAL

<220>

<223> LIGHT CHAIN VARIABLE REGION OF CLONE CL-2C

<400> 61

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly  
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn  
20 25 30

Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile  
35 40 45

Tyr Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Ala Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser  
65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Trp Ser Trp Pro Thr  
85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys  
100 105

<210> 62

<211> 123

<212> PRT

<213> ARTIFICIAL

<220>

<223> HEAVY CHAIN VARIABLE REGION OF CLONE CL-2C

<400> 62

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Met Lys Pro Gly Ser  
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Trp Tyr  
20 25 30

Trp Leu Glu Trp Val Arg Gln Ala Pro Gly His Gly Leu Glu Trp Met  
35 40 45

Gly Glu Ile Asp Pro Gly Thr Phe Thr Thr Asn Tyr Asn Glu Lys Phe  
50 55 60

Lys Ala Arg Val Thr Phe Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr  
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95

Ala Arg Phe Ser His Phe Ser Gly Ser Asn Tyr Asp Tyr Phe Asp Tyr  
 100 105 110

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser  
 115 120

<210> 63  
 <211> 107  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> LIGHT CHAIN VARIABLE REGION OF CLONE CL-5I

<400> 63

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly  
 1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn  
 20 25 30

Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile  
 35 40 45

Tyr Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Ala Arg Phe Ser Gly  
 50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser  
 65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Trp Ser Trp Pro Thr  
 85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys  
 100 105

<210> 64  
 <211> 123  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> HEAVY CHAIN VARIABLE REGION OF CLONE CL-5I

<400> 64

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Met Lys Pro Gly Ser  
 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Met Tyr  
 20 25 30

Trp Leu Glu Trp Val Arg Gln Ala Pro Gly His Gly Leu Glu Trp Met  
 35 40 45

Gly Glu Ile Asp Pro Gly Thr Phe Glu Thr Asn Tyr Asn Glu Lys Phe  
 Page 20

50

55

60

Lys Ala Arg Val Thr Phe Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr  
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95

Ala Arg Phe Ser His Phe Ser Gly Ser Asn Tyr Asp Tyr Phe Asp Tyr  
100 105 110

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser  
115 120

<210> 65  
<211> 107  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> LIGHT CHAIN VARIABLE REGION OF CLONE CL-5A

<400> 65

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly  
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn  
20 25 30

Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile  
35 40 45

Tyr Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Ala Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser  
65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Trp Ser Trp Pro Thr  
85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys  
100 105

<210> 66  
<211> 123  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> HEAVY CHAIN VARIABLE REGION OF CLONE CL-5A

<400> 66

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Met Lys Pro Gly Ser  
1 5 10 15



Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Trp Tyr  
 20 25 30  
 Trp Leu Glu Trp Val Arg Gln Ala Pro Gly His Gly Leu Glu Trp Met  
 35 40 45  
 Gly Glu Ile Glu Pro Gly Thr Glu Thr Thr Asn Tyr Asn Glu Lys Phe  
 50 55 60  
 Lys Ala Arg Val Thr Phe Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr  
 65 70 75 80  
 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Ala Arg Phe Ser His Phe Ser Gly Ser Asn Tyr Asp Tyr Phe Asp Tyr  
 100 105 110  
 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser  
 115 120

<210> 67  
 <211> 107  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> LIGHT CHAIN VARIABLE REGION OF CLONE CL-2B

<400> 67

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly  
 1 5 10 15  
 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn  
 20 25 30  
 Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile  
 35 40 45  
 Tyr Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Ala Arg Phe Ser Gly  
 50 55 60  
 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser  
 65 70 75 80  
 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Trp Ser Trp Pro Thr  
 85 90 95  
 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys  
 100 105

<210> 68

<211> 123  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> HEAVY CHAIN VARIABLE REGION OF CLONE CL-2B

<400> 68

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Met Lys Pro Gly Ser  
 1 5 10 15  
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Tyr Tyr  
 20 25 30  
 Trp Leu Glu Trp Val Arg Gln Ala Pro Gly His Gly Leu Glu Trp Met  
 35 40 45  
 Gly Glu Ile Asp Pro Gly Thr Phe Thr Thr Asn Tyr Asn Glu Lys Phe  
 50 55 60  
 Lys Ala Arg Val Thr Phe Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr  
 65 70 75 80  
 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Ala Arg Phe Ser His Phe Ser Gly Ser Asn Tyr Asp Tyr Phe Asp Tyr  
 100 105 110  
 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser  
 115 120

<210> 69  
 <211> 107  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> LIGHT CHAIN VARIABLE REGION OF CLONE CL-1136-2C

<400> 69

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly  
 1 5 10 15  
 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn  
 20 25 30  
 Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile  
 35 40 45  
 Tyr Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Ala Arg Phe Ser Gly  
 50 55 60  
 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser  
 65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Trp Ser Trp Pro Thr  
 85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys  
 100 105

<210> 70  
 <211> 123  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> HEAVY CHAIN VARIABLE REGION OF CLONE CL-1136-2C

<400> 70

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser  
 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Met Tyr  
 20 25 30

Trp Leu Glu Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met  
 35 40 45

Gly Glu Ile Ser Pro Gly Thr Phe Thr Thr Asn Tyr Asn Glu Lys Phe  
 50 55 60

Lys Ala Arg Val Thr Phe Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr  
 65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

Ala Arg Phe Ser His Phe Ser Gly Ser Asn Tyr Asp Tyr Phe Asp Tyr  
 100 105 110

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser  
 115 120

<210> 71  
 <211> 108  
 <212> PRT  
 <213> Homo sapiens

<400> 71

Asp Ser Asn Pro Arg Gly Val Ser Ala Tyr Leu Ser Arg Pro Ser Pro  
 1 5 10 15

Phe Asp Leu Phe Ile Arg Lys Ser Pro Thr Ile Thr Cys Leu Val Val  
 20 25 30

Asp Leu Ala Pro Ser Lys Gly Thr Val Asn Leu Thr Trp Ser Arg Ala  
 35 40 45

Ser Gly Lys Pro Val Asn His Ser Thr Arg Lys Glu Glu Lys Gln Arg  
 50 55 60

Asn Gly Thr Leu Thr Val Thr Ser Thr Leu Pro Val Gly Thr Arg Asp  
 65 70 75 80

Trp Ile Glu Gly Glu Thr Tyr Gln Cys Arg Val Thr His Pro His Leu  
 85 90 95

Pro Arg Ala Leu Met Arg Ser Thr Thr Lys Thr Ser  
 100 105

<210> 72  
 <211> 12  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> PEPTIDE DERIVED FROM CH3 DOMAIN OF IGE

<220>  
 <221> misc\_feature  
 <222> (7)..(7)  
 <223> Xaa can be any naturally occurring amino acid

<220>  
 <221> misc\_feature  
 <222> (9)..(10)  
 <223> Xaa can be any naturally occurring amino acid

<220>  
 <221> misc\_feature  
 <222> (12)..(12)  
 <223> Xaa can be any naturally occurring amino acid

<400> 72

Asn Pro Arg Gly Val Ser Xaa Tyr Xaa Xaa Arg Xaa  
 1 5 10

<210> 73  
 <211> 12  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> PEPTIDE DERIVED FROM CH3 DOMAIN OF IGE

<400> 73

Asn Pro Arg Gly Val Ser Ala Tyr Leu Ser Arg Pro  
 1 5 10

<210> 74  
 <211> 9  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> PEPTIDE DERIVED FROM CH3 DOMAIN OF IGE

<220>  
<221> misc\_feature  
<222> (6)..(6)  
<223> Xaa can be any naturally occurring amino acid

<220>  
<221> misc\_feature  
<222> (9)..(9)  
<223> Xaa can be any naturally occurring amino acid

<400> 74

Leu Pro Arg Ala Leu Xaa Arg Ser Xaa  
1 5

<210> 75  
<211> 9  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> PEPTIDE DERIVED FROM CH3 DOMAIN OF IGE

<400> 75

Leu Pro Arg Ala Leu Met Arg Ser Thr  
1 5

<210> 76  
<211> 12  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> PEPTIDE DERIVED FROM CH3 DOMAIN OF IGE

<400> 76

His Pro His Leu Pro Arg Ala Leu Met Arg Ser Thr  
1 5 10

<210> 77  
<211> 12  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> PEPTIDE DERIVED FROM CH3 DOMAIN OF IGE

<400> 77

Leu Pro Arg Ala Leu Met Arg Ser Thr Thr Lys Thr  
1 5 10

INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US04/24360

A. CLASSIFICATION OF SUBJECT MATTER  
 IPC(7) : C07K 7/00; C07K 16/18; A61K 39/00  
 US CL : 530/327, 328, 387.1, 387.3; 424/185.1; 435/810  
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED  
 Minimum documentation searched (classification system followed by classification symbols)  
 U.S. : 530/327, 328, 387.1, 387.3; 424/185.1; 435/810

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
 MEDLINE, EMBASE, BIOSIS, SCISEARCH, CAPLUS on STN

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 99/67293 (UNITED BIOMEDICAL INC) 29 December 1999 (29.12.99), see page 35, 27, 54, 62-63, abstract.	1-3, 5-8, 10-11, 13-17 and 21
Y	US 6,180,370 B1 (QUEEN et al) 30 January 2001 (30.01.2001), col. 3, lines 27-48.	9 and 18-20

Further documents are listed in the continuation of Box C.  See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search: 19 February 2005 (19.02.2005)  
 Date of mailing of the international search report: 19 APR 2005

Name and mailing address of the ISA/US: Mail Stop PCT, Attn: ISA/US, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, Facsimile No. (703) 305-3230  
 Authorized officer: Phuong Huynh, Telephone No. (571) 272-1600